WO2011140194A1 - Ophthalmic composition - Google Patents

Ophthalmic composition Download PDF

Info

Publication number
WO2011140194A1
WO2011140194A1 PCT/US2011/035147 US2011035147W WO2011140194A1 WO 2011140194 A1 WO2011140194 A1 WO 2011140194A1 US 2011035147 W US2011035147 W US 2011035147W WO 2011140194 A1 WO2011140194 A1 WO 2011140194A1
Authority
WO
WIPO (PCT)
Prior art keywords
dorzolamide
timolol
ophthalmic composition
polysorbate
test
Prior art date
Application number
PCT/US2011/035147
Other languages
French (fr)
Inventor
Jun Inoue
Tapan Shah
Original Assignee
Senju Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Usa, Inc. filed Critical Senju Usa, Inc.
Priority to US13/695,930 priority Critical patent/US20130053374A1/en
Priority to MX2012012846A priority patent/MX2012012846A/en
Priority to EP20110778244 priority patent/EP2566487A4/en
Priority to CA2797123A priority patent/CA2797123A1/en
Priority to CN2011800332340A priority patent/CN103096901A/en
Priority to JP2013509213A priority patent/JP2013528589A/en
Priority to KR1020127031915A priority patent/KR20130121685A/en
Publication of WO2011140194A1 publication Critical patent/WO2011140194A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to an ophthalmic composition
  • a hyperbranched polymer comprising a hyperbranched polymer.
  • the hyperbranched polymer of the present invention may be any hyperbranched polymer which is pharmaceutically acceptable, e.g., a hyperbranched polymer with a Polyethyleneimine, Polypropyleneimine or Polyester.
  • COSOPT ® and TRUSOPT ® are commercially available topical ophthalmic solutions developed by Merck for treating an eye disease called glaucoma.
  • the active ingredient is Dorzolamide exclusively.
  • the active ingredients are Dorzolamide and Timolol (beta blocker).
  • Dorzolamide is a carbonic anhydraze inhibitor with the aqueous solubility of 40 mg/mL at pH 4.0-5.5. It is a white to off-white, crystalline powder, which is soluble in water and slightly soluble in methanol and ethanol.
  • Dorzolamide has a relatively low aqueous solubility in solutions with pH between 6.4 and 8.5, mainly because of Dorzolamide's non-ionic behavior in that physiological pH range.
  • AZOPT ® (Brinzolamide ophthalmic suspension) 1% is a sterile, aqueous suspension of Brinzolamide, which has been formulated to be readily suspended and slow settling, following shaking.
  • AZOPT ® is developed by Alcon and contains Brinzolamide as active ingredient. The formulation has a pH of approximately 7.5 and an osmolality of 300 mOsm/kg. It is instilled for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
  • Brinzolamide's pKa values are 5.9 (amine) and 8.4 (primary sulfonamide), allowing it to act as an acid or a base (ampholyte) depending upon the pH.
  • Brinzolamide is significantly less protonated ( ⁇ 10%) at physiological pH.
  • Brinzolamide has relatively low aqueous solubility in solutions with pH between 5.9 and 8.4, mainly because of Brinzolamide's nonionic (lipophilic) behavior in that pH range.
  • Dendritic polymers are tree-like polymers that can be classified into two main types based on their branching architecture as "perfectly branched” (dendrimers) and “imperfectly branched” (hyperbranched polymers or HP).
  • Hyperbranched polymers are molecular constructions having a branched structure, generally around a core. Unlike dendrimers, the structure of hyperbranched polymers generally lacks symmetry, as the base units or monomers used to construct the hyperbranched polymer can be of diverse nature and their distribution is non-uniform.
  • the branches of the polymer can be of different natures and lengths. The number of base units, or monomers, may be different depending on the different branching.
  • hyperbranched polymers can have: an extremely branched structure, around a core; successive generations or layers of branching; a layer of end chains.
  • Hyperbranched polymers are generally derived from the polycondensation of one or more monomers AB X , A and B being reactive groups capable of reacting together, x being an integer greater than or equal to 2.
  • a and B being reactive groups capable of reacting together, x being an integer greater than or equal to 2.
  • An end group T can be reacted with the hyperbranched polymer to obtain a particular functionality on the ends of chains.
  • Hyperbranched polymers are mainly identified by their core type and their terminal groups.
  • Examples of a core type for a hyperbranched polymer are polyethylenimine, polypropylenimine, polyglycol, polyether, polyester, etc.
  • a hyperbranched polymer with a polyester core may be referred to as a hyperbranched polyester.
  • Examples of terminal or surface functional groups of hyperbranched polymers are amine, hydroxyl, carboxylic acid, a fatty acid, polyethylene glycol (PEG), polyester, etc. See U.S. Patent 6,432,423, U.S. Patent 7,097,856, and U.S. Patent Publication 2006/0204472, the contents of which are incorporated herein by reference.
  • hyperbranched polymers In contrast to the "structurally perfect" dendrimers prepared by multi-step synthesis, somewhat less perfect hyperbranched polymers can be synthesized in one-step reactions. Thus, unlike dendrimers, hyperbranched polymers are rapidly prepared with no purification steps needed for their preparation. Consequently, hyperbranched polymers are significantly less expensive than dendrimers. Thus it makes hyperbranched polymers amenable for large-scale in vivo trials and bringing highly branched polymers as candidates for drug delivery of even common drugs as ibuprofen (Kannan, R.M. et al., Biomedical Applications of Nanotechnology, 2007, John Wiley & Sons Inc., p. 105).
  • An object of the invention is to provide an improved ophthalmic composition, with improved aqueous solubility and corneal permeation of the active agent.
  • hyperbranched polymers are muco- adhesive polymers with a high force of bioadhesion, which provide strong electrostatic interactions between the negatively charged cornea mucin membrane and the cationic hyperbranched polymers.
  • hyperbranched polymers increase the aqueous solubility of carbonic anhydrase inhibitors such as Dorzolamide or Brinzolamide for glaucoma therapy. Additionally, the present inventors have discovered that the aqueous solubility of Dorzolamide or Brinzolamide increases linearly with an increase in the concentration of the hyperbranched polymer. Furthermore, the present inventors have discovered that hyperbranched polymers, such as Bis-MPA hyperbranched polyester with hydroxyl functional groups (2 nd generation), can be safely employed up to 4% (w/v) with no cytotoxic or eye irritation, based on in vitro human corneal epithelial cell culture studies. Additionally, the present inventors have discovered that hyperbranched polymers increase the corneal permeation and partitioning of Dorzolamide and Timolol into intact cornea, and increase the partitioning of Dorzolamide and Timolol into the lipophilic cornea membrane.
  • the present invention provides:
  • An ophthalmic composition comprising a hyperbranched polymer, wherein the hyperbranched polymer comprises a terminal functional group selected from the group consisting of an amine group, a hydroxyl group, a fatty acid group, and Polyethylene Glycol (PEG).
  • a hyperbranched polymer comprises a terminal functional group selected from the group consisting of an amine group, a hydroxyl group, a fatty acid group, and Polyethylene Glycol (PEG).
  • the beta-blocker is selected from the group consisting of Carteolol, Levobunolol, Betaxolol, Metipranolol, Timolol and Propranolol.
  • concentration of the hyperbranched polymer is in the range from 0.001 % to 4% (w/v).
  • An ophthalmic composition comprising a hyperbranched polyester, Timolol, Dorzolamide, and Polysorbate 80, wherein the hyperbranched polyester comprises a terminal functional group selected from the group consisting of polyester hydroxyl group, a fatty acid group, and PEG.
  • An ophthalmic composition comprising a hyperbranched polyester, Timolol, Brinzolamide, and Polysorbate 80, wherein the hyperbranched polyester comprises a terminal functional group selected from the group consisting of polyester hydroxyl group, a fatty acid group, and PEG.
  • Figure 1 shows the pH-solubility profile of Dorzolamide in 0.1 % (w/v) phosphate buffer.
  • Figure 2 shows the dependence of hyperbranched polymer concentration on the aqueous solubility of Dorzolamide in 0.1% (w/v) phosphate buffer at pH 5.65.
  • Figure 3 shows the dependence of hyperbranched polymer concentration on the aqueous solubility of Dorzolamide in 0.1 % (w/v) phosphate buffer at pH 7.
  • Figure 4 shows the effect of a combination of PEG 8000 and hyperbranched polymer (Lupasol ® PS) with various concentrations on the aqueous solubility of Dorzolamide at pH 7.
  • Figure 5 shows the viscosity as a function of shear rate at 20 °C of different solutions in 0.1% (w/v) phosphate buffer.
  • Figure 6 shows the force of bioadhesion at pH 7 and shear rate of 80 s "1 .
  • Figure 7 shows the maximum aqueous solubility of Dorzolamide at pH 5.65 and pH 7 with addition of additives in the presence of 0.5% Timolol in the aqueous solution in all cases.
  • Figure 8 shows the maximum Dorzolamide solubility at pH 7 with different combinations of additives in the presence of 0.5% Timolol.
  • Figure 9 shows the schematic of a standard side by side diffusion cell.
  • Figure 12 shows the mean percentage total corneal permeation of Dorzolamide and Timolol after 3 hours for a formulation containing Lupasol ® PS hyperbranched polymer.
  • Figure 13 shows the mean corneal permeability coefficients of Dorzolamide and Timolol for a formulation containing Lupasol PS hyperbranched polymer.
  • Figure 14 shows the mean diffusion coefficients of Dorzolamide and Timolol for permeation through intact rabbit corneas for a formulation containing Lupasol ® PS hyperbranched polymer.
  • Figure 15 shows the mean partition coefficients of Dorzolamide and Timolol for permeation through intact rabbit corneas for a formulation containing Lupasol ® PS hyperbranched polymer.
  • Figure 16 shows the aqueous solubility of Brinzolamide in 10 mM phosphate buffer at different pH values.
  • Figure 17 shows the maximum aqueous solubility of Brinzolamide at pH 7 with addition of additives in the absence and presence of 0.5% Timolol in the aqueous solution.
  • Figure 20 shows the mean percentage total corneal permeation of Dorzolamide and Timolol after 2 hours for a formulation containing Boltorn ® H20 hyperbranched polymer.
  • Figure 21 shows the mean corneal permeability coefficients of Dorzolamide and Timolol for a formulation containing Boltorn ® H20 hyperbranched polymer.
  • Figure 22 shows the mean diffusion coefficients of Dorzolamide and Timolol for permeation through intact rabbit corneas for a formulation containing Boltorn ® H20 hyperbranched polymer.
  • Figure 23 shows the mean partition coefficients of Dorzolamide and Timolol for permeation through intact rabbit corneas for a formulation containing Boltorn ® H20 hyperbranched polymer.
  • Figure 24 shows the maximum aqueous solubility of Brinzolamide at pH 7.4 with addition of Boltorn ® W3000 (amphiphilic HP) in the presence of 0.5% (w/v) Timolol in the emulsion solution.
  • Figure 27 shows the mean percentage total corneal permeation of Dorzolamide and Timolol after 3 hours for a formulation containing Boltorn ® W3000 hyperbranched polymer.
  • Figure 28 shows the mean corneal permeability coefficients of Dorzolamide and Timolol for a formulation containing Boltorn ® W3000 hyperbranched polymer.
  • Figure 29 shows the mean diffusion coefficients of Dorzolamide and Timolol for permeation through intact rabbit cornea for a formulation containing Boltorn ® W3000 hyperbranched polymer.
  • Figure 30 shows the mean partition coefficients of Dorzolamide and Timolol for permeation through intact rabbit cornea for a formulation containing Boltorn ® W3000 hyperbranched polymer.
  • Figure 31 shows the maximum aqueous solubility of Brinzolamide at pH 7.4 with addition of 2 nd Bis-MPA hyperbranched polyester or 3 rd Bis-MPA hyperbranched polyester in the presence of 0.5% (w/v) Timolol.
  • Figure 32 shows the in vitro human corneal epithelium cell viability of different concentrations of hyperbranched polyesters (hydroxyl groups generation 2 and 3), and AZOPT ® .
  • Figure 33 shows the cytotoxicity of Bis-MPA hyperbranched polyester for different concentrations.
  • Figure 34 shows the solubility and stability of Dorzolamide at pH 7.4 with addition of Bis-MPA hyperbranched polyester and non-ionic surfactants in the presence of 0.5% (w/v) Timolol.
  • Figure 35 shows the maximum aqueous solubility of Dorzolamide at pH 7.4 with addition of different additives in the presence of 0.5% (w/v) Timolol.
  • Figure 36 shows intact cornea permeation profile of Dorzolamide for formulation containing Bis MPA hyperbranched polyester (2 nd generation).
  • Figure 37 shows intact cornea permeation profile of Timolol for formulation containing Bis MPA hyperbranched polyester (2 nd generation).
  • Figure 38 shows the mean percentage total corneal permeation of Dorzolamide and Timolol after 3 hours for formulation containing Bis MPA hyperbranched polyester (2 nd generation).
  • Figure 39 shows the permeability coefficients of Dorzolamide and Timolol for formulation containing Bis MPA hyperbranched polyester (2 nd generation).
  • Figure 40 shows the partition coefficients of Dorzolamide and Timolol for formulation containing Bis MPA hyperbranched polyester (2 nd generation).
  • compositions of the present invention are topically administratable therapeutic compositions for treatment of conditions of the eye.
  • conditions of the eye include glaucoma, and ocular diseases such as cataract, conjunctivitis, infection, inflammation or retinopathy.
  • the present invention includes an ophthalmic composition comprising a hyperbranched polymer.
  • the hyperbranched polymer according to the present invention may be any hyperbranched polymer which is pharmaceutically acceptable, e.g., a hyperbranched polymer with a Polyethyleneimine, Polypropylenimine or a polyester core.
  • the molecular weight of the hyperbranched polymer in the ophthalmic compositions of the present invention is in the range of from 1 ,000 to 750,000 Daltons, preferably in the range of 1 ,000 to 12,000 Daltons.
  • the molecular weight is weight average molecular weight measured by dynamic light scattering.
  • the concentration of the hyperbranched polymer in the ophthalmic compositions of the present invention is in the range from 0.001% to 10% (w/v), preferably in the range from 0.001% to 5% (w/v), more preferably in the range from 0.001% to 4% (w/v), more preferably in the range from 0.01% to 4% (w/v), more preferably in the range of 0.01 % to 3% (w/v).
  • the ophthalmic composition discussed above may also comprise a carbonic anhydrase inhibitor.
  • Carbonic anhydrase inhibitors are a class of pharmaceuticals that suppress the activity of carbonic anhydrase, and are known to be useful as anti-glaucoma agents. Examples of carbonic anhydrase inhibitors which may be present in the ophthalmic compositions of the present invention are Dorzolamide, Brinzolamide or Acetazolamide.
  • the ophthalmic composition discussed above may also comprise a non-ionic surfactant.
  • the non-ionic surfactant may be any non-ionic surfactant which is known as a pharmaceutically acceptable additive, for example, Polysorbate 80, PEG 8000, HPMC or HEC.
  • the ophthalmic compositions of the present invention are advantageously used after being adjusted to a pH range which is conventionally adopted for topical application to the eye, and is normally employed after being adjusted to a pH of 3 to 8, preferably a pH of 5 to 8.
  • a pH range which is conventionally adopted for topical application to the eye
  • hydrochloric acid, acetic acid, sodium hydroxide, etc. can be used.
  • the ophthalmic compositions of the present invention may also comprise a beta-blocker.
  • Beta-blockers are known to reduce the pressure within the eye (the intraocular pressure), and thus, are used to lessen the risk of damage to the optic nerve and loss of vision in patients with glaucoma.
  • the beta-blocker in the ophthalmic compositions of the present invention may be any beta-blocker which is known as acceptable in ophthalmic compositions, such as Carteolol, Levobunolol, Betaxolol, Metipranolol, Timolol and Propranolol.
  • a first specific embodiment of the present invention is an ophthalmic composition
  • a hyperbranched polymer Timolol, Dorzolamide, PEG 8000 and Polysorbate 80.
  • compositions preferably comprise about 0.001 % to 10% (w/v) of the hyperbranched polymer, most preferably about 1 to 5% (w/v), and 0.05 to 1 % (w/v) of Timolol, most preferably about 0.5% (w/v), and about 0.05 to 5% (w/v) of Dorzolamide, most preferably about 0.5 to 2% (w/v), and about 0.05 to 5% (w/v) of PEG 8000, most preferably about 0.5 to 4% (w/v), and about 0.05 to 5% (w/v) of Polysorbate 80, most preferably about 0.5 to 4% (w/v), and are to be administered once or twice a day to each affected eye.
  • a second specific embodiment of the present invention is an ophthalmic composition
  • a hyperbranched polymer comprising a hyperbranched polymer, Timolol, Brinzolamide, PEG 8000 and Polysorbate 80.
  • Such compositions preferably comprise about 0.001 % to 10% (w/v) of the hyperbranched polymer, most preferably about 1 to 5% (w/v), and 0.05 to 1 % (w/v) of Timolol, most preferably about 0.5% (w/v), and about 0.05 to 5% (w/v) of Brinzolamide, most preferably about 0.5 to 2% (w/v), and about 0.05 to 5% (w/v) of PEG 8000, most preferably about 0.5 to 4% (w/v), and about 0.05 to 5% (w/v) of Polysorbate 80, most preferably about 0.5 to 4% (w/v), and are to be administered once or twice a day to each affected eye.
  • a third specific embodiment of the present invention is an ophthalmic composition
  • a hyperbranched polyester Timolol, Dorzolamide, PEG 8000 and Polysorbate 80.
  • compositions preferably comprise about 0.1% to 10% (w/v) of the hyperbranched polyester, most preferably about 1 to 5% (w/v), and 0.05 to 1% (w/v) of Timolol, most preferably about 0.5% (w/v), and about 0.05 to 5% (w/v) of Dorzolamide, most preferably about 0.5 to 2% (w/v), and about 0.05 to 5% (w/v) of PEG 8000, most preferably about 0.5 to 4% (w/v), and about 0.05 to 5% (w/v) of Polysorbate 80, most preferably about 0.5 to 4% (w/v), and are to be administered once or twice a day to each affected eye.
  • a fourth specific embodiment of the present invention is an ophthalmic composition
  • a hyperbranched polyester Timolol, Brinzolamide, PEG 8000 and PEG 8000.
  • compositions preferably comprise about 0.1% to 10% (w/v) of the hyperbranched polyester, most preferably about 1 to 5% (w/v), and 0.05 to 1 % (w/v) of Timolol, most preferably about 0.5% (w/v), and about 0.05 to 5% (w/v) of Brinzolamide, most preferably about 0.5 to 2% (w/v), and about 0.05 to 5% (w/v) of PEG 8000, most preferably about 0.5 to 4% (w/v), and about 0.05 to 5% (w/v) of Polysorbate 80, most preferably about 0.5 to 4% (w/v), and are to be administered once or twice a day to each affected eye.
  • the ophthalmic compositions according to the present invention may comprise a pharmacologically acceptable carrier, excipient or diluent which is known per se and may be formulated by a method known per se for preparing ophthalmic compositions.
  • the ophthalmic compositions of the present invention may be provided in any pharmaceutical dosage form that is conventionally used as an ophthalmic preparation, e.g., eye drops, emulsions, and eye ointments.
  • the eye drop formulation may, for example, be an aqueous formulation, such as ophthalmic solution which is clear solution, ophthalmic suspension, ophthalmic emulsion, as well as non-aqueous formulations, such as non-aqueous ophthalmic solution and non-aqueous ophthalmic suspension.
  • aqueous formulation such as ophthalmic solution which is clear solution, ophthalmic suspension, ophthalmic emulsion, as well as non-aqueous formulations, such as non-aqueous ophthalmic solution and non-aqueous ophthalmic suspension.
  • the ophthalmic solution formulation may contain various additives incorporated ordinarily, such as buffering agents (e.g., phosphate buffers, borate buffers, citrate buffers, tartarate buffers, .acetate buffers, amino acids, Sodium acetate, Sodium citrate and the like), isotonicities (e.g., saccharides such as sorbitol, glucose and mannitol, polyhydric alcohols such as Glycerin, concentrated Glycerin, PEG and Propylene glycol, salts such as Sodium chloride), preservatives or antiseptics (e.g., Benzalkonium chloride, Benzethonium chloride, P- oxybenzoates such as Methyl p-oxybenzoate or Ethyl p-oxybenzoate, Benzyl alcohol, Phenethyl alcohol, Sorbic acid or its salt, Thimerosal, Chlorobutanol and the like), solubilizing aids or stabilizing agents
  • the eye drop formulation in the form of an aqueous suspension may also contain suspending agents (e.g., Polyvinyl pyrrolidone, Glycerin monostearate) and dispersing agents (e.g., surfactants such as Tyloxapol, ionic polymers such as Sodium alginate) in addition to the additives listed above, whereby ensuring that the eye drop formulation is a further uniform microparticulate and satisfactorily dispersed aqueous suspension.
  • suspending agents e.g., Polyvinyl pyrrolidone, Glycerin monostearate
  • dispersing agents e.g., surfactants such as Tyloxapol, ionic polymers such as Sodium alginate
  • the eye drop formulation in the form of an aqueous suspension preferably contains Sodium citrate or Sodium acetate as a buffering agent, concentrated Glycerin and/or Propylene glycol as an isotonicity and Polyvinyl pyrrolidone as a suspending agent.
  • a preferred dispersing agent is a surfactant and/or Sodium alginate. Such surfactant is preferably Tyloxapol.
  • the ophthalmic composition of the present invention may be administered to a mammal which is or may be suffering from an ophthalmic disease, such as glaucoma (e.g., a human, rabbit, dog, cat, cattle, horse, monkey).
  • an ophthalmic disease such as glaucoma (e.g., a human, rabbit, dog, cat, cattle, horse, monkey).
  • the concentration of the active agent in the ophthalmic composition of the present invention is about 0.001 to 5 (w/v) %, preferably about 0.01 to 3 (w/v) % contained in an aqueous eye drop formulation when given to an adult, and is given preferably 1 to 8 times a day with a single dose being one to several drops.
  • the ophthalmic compositions of the present invention may contain or may be used together with other appropriate pharmacologically effective substances, for example, steroidal anti-inflammatory agents (Dexamethasone, Prednisolone, Loteprednolm Fluorometholone, Fluocinolone and the like), non-steroidal anti-inflammatory agents (Diclofenac sodium, Pranoprofen, Bromfenac, Ketorolac tromethamine, Napafenac, Flurbiprofen Sodium and the like), antiallergic agents (Tranilast, Ketotifen fumarate, Olopatadine hydrochloride, Sodium Cromoglicate, Potassium Pemirolast, Sodium Nedocromil and the like), antihistamic agents (Epinastine hydrochloride, Azelastine hydrochloride, Azalastine hydrochrilidem, Diphenhydramine hydrochloride and the like), gla
  • steroidal anti-inflammatory agents Disa
  • the ophthalmic compositions of the present invention may be produced by dissolving or dispersing the active agent(s), hyperbranched polymer and optionally the non-ionic surfactant in a solution appropriately containing pharmaceutically acceptable additives, such as isotonicity agents, buffers, preservatives, suspending agents, thickeners, stabilizers, pH adjusting agents, and the like.
  • pharmaceutically acceptable additives such as isotonicity agents, buffers, preservatives, suspending agents, thickeners, stabilizers, pH adjusting agents, and the like.
  • Figure 1 demonstrates that the aqueous solubility of Dorzolamide decreases as the pH increases from 5.65, and reaches a bottom at pH 7. Since COSOPT ® is formulated at pH 5.65,
  • the present inventors discovered that the aqueous solubility of Dorzolamide increased with an increase in the concentration of HP and PEG. In the case of PEG, the solubility also increased linearly with an increase in the molecular weight of the PEG. Further, the Polysorbate 80 assists in dispersing the Dorzolamide molecules and inhibits the precipitation in water in presence of PEG.
  • Brookfield Rotational L VDVE viscometer was employed for all measurements. Spindle with code number 18 was used for all viscosity measurements. A factor of 1 .32 was used to convert rpm to shear rate (s 1 ) as per the manual.
  • a solution of 15% (w/v) of gastric mucin was prepared in 0.1% (w/v) phosphate buffer at pH 7. The individual viscosities 0.5% (w/v) and 1 % (w/v) of Lupasol PS in phosphate buffer solution were measured. The viscosities of 15% mucin in phosphate buffer were also measured. The viscosity was measured at 20 °C at different shear rates D from 2.6 to 80 s "1 . (Hassan, E.
  • Table 2 Contents (% w/v) of Test Samples.
  • Sample #7 is the original COSOPT market product.
  • the viscosity at 20 °C was measured at different shear rates.
  • the force of bioadhesion was calculated using equations (1 ) and (2), discussed above.
  • the low concentrations of HP in phosphate buffer have relatively less viscosity compared to COSOPT ® (Sample #7) and mucin (Sample #1 ).
  • the viscosities of HP (0.5%, Sample #2 and 1 %, Sample #4) are relatively close to water at high shear rates.
  • the difference between the viscosities of 0.5% (w/v) HP and 1% (w/v) are negligible.
  • the force of bioadhesion was quantified based on the data available from Figure 5 at shear rate of 80 s "1 .
  • High shear rate was chosen since the polymers typically exhibit bioadhesive properties at high shear rates (close to 100 s "1 ).
  • the bioadhesive bond strength of low concentrations (0.5% (w/v) and 1 % (w/v)) of HP-mucin system is almost more than two times to that of COSOPT ® -mucin system.
  • the addition of 2% (w/v) PEG did not change the force of bioadhesion of 1% (w/v) HP- mucin system, suggesting that 2% PEG may not have influence on force of bioadhesion caused by the HP at pH 7.
  • the results shown in Figure 6 indicate that the bioadhesive strengths of low concentrations of HPs are relatively significant compared to the polymers present in COSOPT ® formulation.
  • the bioadhesive phenomenon may be very conducive for increasing the ocular bioavailability of the drug.
  • hyperbranched polymers are bio-adhesive additive materials that could strongly interact with ocular mucin. These bioadhesive forces between mucin and HP could eventually lead to enhancement of the ocular bioavailability of the drug.
  • Table 3 Different Test formulations prepared at pH 5.65 in citrate buffer, and at pH 7 in phosphate buffer.
  • the formulations were again prepared in 10 mM phosphate buffer (Table 3) for the formulations to be tested for Dorzolamide solubility at pH 7 in phosphate buffer rather than citrate buffer.
  • the suspension solutions were first stirred for 10 min at room temperature (with heating up to 60 °C for 5 minutes). After allowing the suspensions to equilibrate at room temperature for an additional 30 minutes, the suspension solutions were then sonicated for 10 minutes and finally filtered through 0.45 ⁇ syringe filters. The filtrates were analyzed for Dorzolamide and Timolol concentration using UPLC with the same condition as EXPERIMENTAL EXAMPLE 1 .
  • the present inventors used HP, PEG, and Polysorbate 80 as solubility enhancer additives. Different combinations were attempted at pH 5.65 and pH 7. As shown in Figure 7, the solubility of Dorzolamide was shown to increase with the addition of additives, compared to the control sample without additives, at pH 5.65 and pH 7 in the presence of Timolol. At pH 5.65, in all cases the solubility of Dorzolamide was above 2%, and therefore the addition of HP or PEG and Polysorbate 80 combination increased solubility of Dorzolamide in the presence of Timolol.
  • Table 4 Composition of receptor solution for in vitro cornea permeation experiment.
  • the corneal area available for permeation was 0.21 1 cm 2 .
  • the receptor compartment was filled with freshly prepared receptor solution at pH 7.2, as per the composition described in Table 4.
  • An aliquot (5 mL) of sample # 1 was placed on the two intact corneas, and the opening of the donor cells was sealed with a glass cover slip.
  • an aliquot (5 mL) of sample #2 was applied on the next two intact corneas.
  • sample #3 aliquot (5 mL) was applied on the remaining two intact corneas.
  • the receptor fluid (5 mL in each receptor cell) was kept at constant temperature of 34 °C using constant stirring through water jacket in all the six cases.
  • the Dorzolamide and Timolol maleate detection conditions were a gradient 1 % (v/v) Triethylamine (TEA) in water: acetonitrile method, performed at room temperature, with the flow rate of 0.7 mL/min, at 254 nm and 298 nm wavelength and 1 ⁇ injection volume, on BEH C 18 1 .7 ⁇ , 2.1 x 50 mm column.
  • TAA Triethylamine
  • each cornea (free from adhering sclera) was weighed after soaking in de-ionized water. The wet cornea was dried overnight in oven, and reweighed. From the difference of weights, corneal hydration was calculated. The final results of drug permeation were expressed as cumulative amount permeated (Q). The parameters that were calculated are as follows:
  • the corneal hydration was measured based on the net wet weight and dry weight of cornea. Typically, the % (w/w) hydrations for cornea in normal mammalian are in the range of 75-80%. Overall, there was no significant change in the % hydrations for all the test samples, and they were within the desired range in all the cases. Thus, the HP or Polysorbate 80 did not have impact on corneal hydration.
  • Figures 10 and 11 reveal the corneal permeation profiles of Dorzolamide and Timolol, respectively.
  • the time dependent permeation of Dorzolamide and Timolol was carefully examined across the isolated rabbit cornea at 34 °C.
  • the Dorzolamide cumulative total amount permeated through the cornea, and the total amount permeated after 3 hours was relatively higher for the test formulation containing 0.5% (w/v) HP compared to the control sample with no additives.
  • the addition of Polysorbate 80 along with HP enhanced the corneal permeation with more amount of Dorzolamide permeated than the formulation containing only HP.
  • the addition of 0.5% (w/v) HP and 1 % (w/v) Polysorbate 80 enhanced the corneal permeation rate of Dorzolamide and Timolol by about 25-30%. A similar trend was also observed for Timolol ( Figure 1 1).
  • the combination of HP and Polysorbate 80 improved the corneal penetration of active ingredients.
  • Figure 12 shows the percentage total permeation of Dorzolamide and Timolol.
  • HP and Polysorbate 80 increased the percentage of active ingredients (Dorzolamide and Timolol) permeated through the cornea.
  • all test formulations had similar initial concentrations in case of Dorzolamide and Timolol (less than 10% change). Thus, it was easy to determine the influence of each additive under similar pH conditions. In comparing test 2 with test 1 , the significance of using HP as an additive is clearly demonstrated.
  • Figure 13 shows the corneal permeability coefficients of Dorzolamide and Timolol.
  • the permeability coefficient was inversely proportional to the initial concentration of the drug in the donor solution.
  • the permeability coefficients for test 2 and test 3 were higher, suggesting that Dorzolamide in the presence of 0.5% HP has enhanced corneal permeability rate compared to pH 5.65 control formulation (Test 1 ) containing no HP.
  • Test 3 had relatively higher corneal permeability than Test 2, thereby indicating the influence of Polysorbate 80.
  • the Polysorbate 80 may possibly act as a viscosity enhancer, thereby increasing the bioavailability of Dorzolamide and Timolol for corneal permeation.
  • HP promotes encapsulation of Timolol and Dorzolamide, and thus enhances the partitioning of Timolol into corneal epithelium.
  • This theory is also supported by the data in Figure 15.
  • the Timolol and Dorzolamide partition coefficient to the corneal surface for Test 3 is higher than Test 1 , indicating the improvement in partitioning of Timolol and Dorzolamide into lipophilic corneal membrane in presence of 0.5% (w/v) highly functional HP.
  • the improved permeation in the presence of HP is mainly because of improved portioning to the epithelium.
  • the partitioning could be further enhanced by increasing the concentration of HP in the formulation solution.
  • HP enhances corneal permeation mainly because a) molecular encapsulation within the branched structures of highly functional Polyethyleneimine, b) electrostatic interactions between the drug molecules and ionic functional amine groups of HP, and c) the muco-adhesive behavior of charged HP.
  • 0.5% (w/v) HP and 1 % (w/v) Polysorbate 80 enhanced the corneal permeation rate of Dorzolamide and Timolol by about 25-30%.
  • the presence of HP increased the partitioning of Dorzolamide and Timolol at pH 5.65 into the corneal membrane.
  • the 0.5% (w/v) HP and 1 % (w/v) Polysorbate 80 addition to the formulation enhanced the corneal permeation rate of Dorzolamide and Timolol by about 25-30%.
  • the partitioning of active ingredients into the corneal epithelium increases in presence of HP.
  • the combination of HP and Polysorbate 80 could be very effective for increasing the ocular bioavailability of COSOPT ® active ingredients.
  • Solubility enhancement of Brinzolamide in aqueous solution containing HP Liupasol ® PS
  • HP Liupasol ® PS
  • HP and Polysorbate 80 or PEG and Polysorbate 80 combinations at pH 7 in phosphate buffer.
  • Table 7 Different Test formulations prepared in phosphate buffer at pH 7.
  • a suspension of Brinzolamide in phosphate buffer containing 1 % (w/v) was prepared for the control sample. Similar suspensions containing excess of Brinzolamide (> 1 % (w/v)) were also prepared in aqueous solution (10 mM phosphate buffer) containing different combinations of HP, PEG and Polysorbate 80 as per Table 7 above. The final pH was adjusted to 7 with 1 M NaOH. The suspension solutions were first stirred for 10 min at room temperature (with heating up to 60 °C for 5 minutes). After allowing the suspensions to equilibrate at room temperature for additional 30 minutes, the suspension solutions were then sonicated for 10 min and finally filtered through 0.45 ⁇ syringe filters. The filtrates were analyzed for Brinzolamide concentration using UPLC with the same condition as EXPERIMENTAL EXAMPLE 1.
  • Figure 16 shows the Brinzolamide solubility in 10 mM phosphate buffer at different pH values. It is clear that the aqueous solubility of Brinzolamide decreases as the pH increases from 4 towards 7. The solubility of Brinzolamide is least at pH 7, consistent with the complete non- ionic behavior at pH 7. As % ionization of Brinzolamide increases with the increase in pH from 8.4 towards 10, the solubility increases steeply consistent with the anionic nature of Brinzolamide in that pH range. The solubility properties are very similar to Dorzolamide. Therefore, it is important to develop a lipophilic Brinzolamide drug with enhanced solubility close to pH 7.4 (pH of tear fluid is 7.44) in order to enhance ocular bioavailability and to decrease eye irritation appearance of Brinzolamide.
  • Polysorbate 80 increases the Brinzolamide solubility by preventing the precipitation. Polysorbate 80 may act as a surfactant thereby reducing the aggregation of Brinzolamide after phase separation in presence of HP. A combination of 0.5% (w/v) HP and 1% (w/v) Polysorbate could be very effective in the presence of 0.5% (w/v) Timolol formulation at pH 7.
  • the improvement in aqueous solubility of Brinzolamide in presence of Timolol was significant with the additions of HP or a combination of PEG and Polysorbate 80 at pH 7.
  • the Polysorbate 80 helps in dispersing the Brinzolamide molecules and inhibits the precipitation in water in presence of PEG.
  • a combination of HP and Polysorbate 80 could be good combination for enhancement of Brinzolamide solubility in presence of Timolol at pH 7. From the results, it can be concluded that HP and Polysorbate 80 significantly enhance the solubility of hydrophobic Brinzolamide in presence of Timolol at pH 7. Hydrophilic PEG also turned out to be a Brinzolamide solubility enhancer.
  • Boltorn ® H20 A novel formulation containing the commercially available HP called Boltorn ® H20.
  • the generic definition of Boltorn ® H20 is a HP with polyester core and 16 terminal hydroxyl functional groups. It enhances the solubility of non-ionic (lipophilic) Dorzolamide that is formulated at pH 7 or pH 7.4.
  • HP used in this example are listed in Table 8. It has 16 primary hydroxyl groups per molecule. The solid content is 100% (w/v).
  • the three test solutions were then stirred for 10 minutes at room temperature (with heating up to 60 °C for 5 minutes). After stirring, the solution was sonicated for 5 minutes.
  • the solutions with HP were white slurry suspensions before adjusting the pH.
  • the pH was adjusted to 7.4 by using 1 M NaOH or 1 M HC1, and additional buffer was added to make up the exact composition as in Table 8. With the adjustment of pH, suspension solutions were formed in all cases, which were equilibrated by stirring for an additional 15 hours or more at room temperature. The pH of all the sample solutions was measured again to confirm the final desired pH.
  • suspension solutions were used directly as sample donor solutions for the cornea permeation study.
  • the suspensions were filtered through 0.45 ⁇ syringe filters.
  • the in vitro cornea permeation profile results were also compared to the data obtained at pH 5.65 for the control sample containing active ingredients from EXPERIMENTAL EXAMPLE 4.
  • the corneal hydration was measured based on the net wet weight and dry weight of the cornea. Typically, the % hydrations for a cornea in a normal mammal are in the range of 75- 80%. Overall, there was no significant change in the % hydrations for all the test samples, and they were within the desired range in all the cases. Thus, the HP did not have impact on corneal hydration.
  • Figures 18 and 19 reveal the corneal permeation profiles of Dorzolamide and Timolol, respectively.
  • the control sample permeation profile at pH 5.65 from EXPERIMENTAL EXAMPLE 4 was also plotted along with the permeation profiles obtained for Test sample 1 , 2 and 3.
  • the time dependent permeation of Dorzolamide and Timolol was carefully examined across the isolated rabbit cornea at 34 °C.
  • the Dorzolamide cumulative total amount permeated through the cornea, and the total amount permeated after 2 hours was relatively higher for the test formulation containing 0.5% (w/v) HP (Test 2) and 2% (w/v) HP (Test 3) compared to the control sample with no additives.
  • the increased concentration from 0.5% HP to 2% HP showed an increase in the corneal permeation of both active ingredients.
  • the corneal permeation of active ingredients is higher than the market product COSOPT ® (only active ingredients in the formulation) at pH 5.65 (see Figure 19 and Figure 20).
  • the formulation containing 2% (w/v) HP provided significant enhancement in corneal permeation after 2 hours with a higher permeation rate (change in the slope).
  • HP improved the corneal penetration of active ingredients, when compared to the market products known as COSOPT ® or TRUSOPT ® or AZOPT ® , which are used for glaucoma treatment.
  • Figure 20 shows the percentage total permeation of Dorzolamide and Timolol after 2 hours.
  • HP increased the percentage of active ingredients (Dorzolamide and Timolol) permeated through the cornea.
  • all test formulations had different initial concentrations in the case of Dorzolamide, and similar concentrations of Timolol (less than 10% change).
  • Different initial solubility of Dorzolamide is mainly because of the increased solubility by HP.
  • Test 2 and Test 3 in comparison with Test 1 the significance of using HP as an additive it is clear from Figure 20.
  • the slopes from Figure 19 and 20 up to 2 hours were used in order to determine the corneal permeability, partition coefficient and diffusion coefficient.
  • Figure 21 shows the corneal permeability coefficients of Dorzolamide and Timolol.
  • the permeability coefficient was inversely proportional to the initial concentration of the drug in the donor solution.
  • the permeability coefficients for Test 2 and Test 3 are higher, suggesting that dorozamide in the presence of HP has an enhanced corneal permeability rate compared to the control formulation (Test 1 ) containing no HP.
  • Test 3 had a relatively higher corneal permeability than Test 2, thereby indicating the influence of increasing the concentration of HP.
  • HP promotes the encapsulation of Timolol and Dorzolamide, and thus enhances the partitioning of Timolol and Dorzolamide into the corneal epithelium.
  • This theory is also supported by the data suggested in Figure 23.
  • the Timolol and Dorzolamide partition coefficient to the corneal surface for Tests 2 and 3 were higher than Test 1 , indicating the improvement in partitioning of Timolol and Dorzolamide into lipophilic corneal membrane in the presence of highly functional (hydroxyl group) HP.
  • the improved permeation in the presence of HP is mainly because of improved partitioning to the epithelium.
  • the permeation was further enhanced by increasing the concentration of HP in the formulation solution from 0.5 % to 2% (w/v).
  • the partition coefficient and permeability coefficient did not change significantly by increasing the concentration of HP, since these parameters will not be a function of the concentration of the material.
  • Hyperbranched polyester with amphiphilic terminal groups The properties of HP used in this experiment are described in Table 12. The HP has 50 primary hydroxyl groups per molecule, and the solid content is 55% (w/w).
  • Table 13 shows the different test samples formulations which were prepared in 10 mM phosphate buffer at pH 7.4.
  • the emulsion was prepared by slowing dispersing water to the weighed amount of waxed Boltorn ® W3000 to make 5% (w/v) emulsion with continuous stirring and heating at 60-70 °C for at least 30 minutes, followed by continuous vigorous stirring for an additional 15 hours, to obtain a homogeneous emulsion mixture in a flask. 10 mM phosphate buffer was added to the appropriately weighed mass of solid active ingredients and stirred thoroughly for 15 minutes. Secondly, the effective volume of 5% (w/v) HP emulsion solution was diluted appropriately to make up the exact concentrations described in Table 13. The sample test emulsion solutions were then stirred for 10 minutes at room temperature (with heating up to 60 °C for 5 minutes).
  • the emulsion solution was sonicated for 5 minutes. After allowing the complete emulsion of all the active and non-active ingredients, the pH was adjusted to 7.4 by using 1 M NaOH, and additional buffer was added to make up the exact compositions in Table 13. With the adjustment of the pH, the emulsion solutions were further equilibrated by stirring for an additional 15 hours or more at room temperature. The pH of all the sample emulsion solutions was measured again to confirm the final desired pH of 7.4. The filtrates were analyzed for CAI concentration using UPLC with the same condition as EXPERIMENTAL EXAMPLE 1.
  • Table 15 Solubility of active pharmaceutical ingredient in test formulations.
  • Table 16 Percentage corneal hydration calculation.
  • the corneal hydration was measured based on the net wet weight and dry weight of the cornea.
  • the % (w/w) hydrations for a cornea in a normal mammal are in the range of 75-80%.
  • Tests 1 and 3 are both above 80%.
  • there is no difference in the calculated values of partition and permeability coefficient suggesting that there could not be any corneal damage due to higher hydration %.
  • Figures 25 and 26 reveal the corneal permeation profiles of Dorzolamide and Timolol, respectively.
  • the time dependent permeation of Dorzolamide and Timolol was examined carefully across the isolated rabbit cornea at 34 °C.
  • the Dorzolamide cumulative total amount permeated through the cornea, and the total amount permeated after 2 hours was relatively higher for the test formulation containing 2% (w/v) HP (Test 2) compared to the control sample with no additive at pH 7.4 (Test 1 ).
  • the total permeation of Dorzolamide of Test 2 (novel formulation) was comparable to the Test 3 permeation profile for Dorzolamide.
  • Test 1 could be more comfortable for the patient since it is prepared at pH 7.4, compared to the market product which is prepared at pH 5.65.
  • the permeation could be further increased by increasing the concentration of the HP.
  • a dendritic polyester HP with amphiphilic functional groups improves the corneal penetration of active ingredients compared to the market products, known as COSOPT ® or TRUSOPT ® or AZOPT ® , which are used for glaucoma treatment.
  • Figure 27 shows the percentage total permeation of Dorzolamide and Timolol after 3 hours.
  • the presence of HP increases the percentage of the active ingredients (Dorzolamide and Timolol) permeated through the cornea (see Test 2).
  • Test 2 prepared at pH 7.4, had a Dorzolamide total % permeation which was slightly greater than Test 3, which is prepared at pH 5.65.
  • Test 3 prepared at pH 7.4
  • Test 3 prepared at pH 5.65.
  • Figure 27 demonstrates the significance of using HP as an additive. The slopes from Figure 26 and 27 were used in order to determine the corneal permeability, partition coefficient and diffusion coefficient.
  • Figure 28 shows the corneal permeability coefficients of Dorzolamide and Timolol.
  • the permeability coefficient is inversely proportional to the initial concentration of the drug in the donor solution.
  • the permeability coefficients for Test 2 are higher compared to the control samples at pH 7.4 and pH 5.65, thus suggesting that active pharmaceutical ingredient in presence of HP has enhanced corneal permeability rate compared to the control formulations (Tests 1 and 3) containing no HP.
  • Test 3 had relatively higher corneal permeability than Test 2, thereby indicating the influence of pH.
  • the active pharmaceutical ingredient at physiological pH is more conducive for permeation for similar solubilities.
  • the Timolol and Dorzolamide partition coefficients to the corneal surface for Test 2 were higher than Tests 1 and 3, thus indicating the improvement in partitioning of Timolol and Dorzolamide into lipophilic corneal membrane in the presence of a highly functional (amphiphilic) HP.
  • the improved permeation in the presence of HP is mainly because of improved partitioning to the epithelium.
  • the permeation can be further enhanced by increasing the concentration of HP in the formulation solution from 2% to 5% (w/v).
  • BMPA-HP is a hyperbranched polymer with dimethylolpropionic acid (Bis-MPA) polyester core and terminal hydroxyl (OH) functional groups.
  • the number of terminal hydroxyl functional groups depends on the generation of the hyperbranched polyester. The generation is defined by the number of branching layers or the extent of branching from the core to the terminal functional groups. For example, the 2 nd generation BMPA hyperbranched polyester contains 16 hydroxyl groups while the 3 rd generation contains 32 hydroxyl groups.
  • the structure of BMPA-HP is shown below.
  • Table 18 shows the different test sample emulsions, except the control solution, to be prepared in 10 mM phosphate buffer at pH 7.4.
  • HCE Human Corneal Epithelium
  • the samples were prepared in accordance with Table 19 below, in saline phosphate buffer (with the exception of AZOPT ® ) and sterilized using a 0.2 ⁇ sterile syringe filter. 0.02% BAK was used as a positive control.
  • the reconstructed human corneal epithelium was purchased from Skin Ethics laboratory (France).
  • Tissue conditioning at least 2 hours at 37 °C, 5% C0 2) > 95% humidity
  • the percentage viability of each of the treated cultures was calculated from the percentage MTT conversion in the test chemical treated cultures relative to the corresponding negative controls (100% viable).
  • Percentage viability [individual OD C h em icai/mean OD negat j ve controi]xl 00.
  • HCE viability classification prediction model NI (viability > 60%), I (viability ⁇ 60%), i.e., the product is classified as an irritant (according to in vivo classifications) if the percentage of viability compared to the negative control obtained for the test product is ⁇ 60%.
  • the percentage viability of different samples was calculated using the equation for percentage viability described above, in the experimental section. Samples with viability of less than 60% were considered irritants. The standard deviation of the cell viability based on triplicates was less than 7% for all the samples.
  • the results from the cytotoxicity study reveal that ophthalmic samples with up to 4% (w/v) of 3 rd BMPA-HP will be a non-eye irritants, with greater than 60% cell viability. (See Figure 32.)
  • the results from Figure 32 also reveal that AZOPT ® could be cytotoxic against corneal epithelim cell with less than 50% cell viability for an application time of 1 hour.
  • the sample containing 5% (w/v) Bis-MPA generation 2 also caused eye irritation with less than 60% cell viability.
  • the rate of epithelial cell death increased with the increase in the concentration dose and the generation (molar mass and extent of branching).
  • the AZOPT ® market product it causes eye irritation with less than 50% cell viability, possibly due to 0.01% (w/v) of BAK with exposure time of one hour.
  • Solubility enhancement of CAI containing BMPA-HP or a combination of non-ionic surfactants and BMPA-HP Solubility enhancement of CAI containing BMPA-HP or a combination of non-ionic surfactants and BMPA-HP.
  • the 10 mM phosphate buffer was added to the appropriate weighed mass of solid active ingredients and stirred thoroughly for 15 minutes. After complete dissolution of active pharmaceutical ingredient, hyperbranched 2 nd BMPA-HP was added to the solution. After HP was dissolved, PEG 8000 was added as per the formulation concentration needed. The sample test solutions were then stirred for 10 minutes at room temperature (with heating up to 60 °C for 5 minutes). After stirring, the solution was sonicated for 20 minutes. After allowing the complete dissolution of all the active and non active ingredients, the pH was adjusted to 7.4 by using 1 M NaOH and additional buffer was added to make up the exact compositions as per Tables 20 and 21.
  • the formulations were further equilibrated by stirring for additional 15 hours or more at room temperature.
  • the samples were filtered through 0.45 um syringe filter.
  • Polysorbate 80 was added to the final formulation.
  • sample number 3 the formulation is equilibrated at 60 °C (24 hours) after pH adjustment, then Polysorbate 80 was added.
  • Table 20 Contents of Dorzolamide and Timolol, Appearance and pH of Samples at room temperature.
  • Table 21 Contents of Dorzolamide and Timolol, Appearance and pH of Samples at 60 °C.
  • 2" BMPA-HP was studied as a solubility enhancer additive.
  • the solubility of Dorzolamide is shown to increase with the additions of 4% (w/v) HP and 2% (w/v) PEG.
  • the concentration of Dorzolamide decreases steadily for the formulation containing 4% (w/v) HP and 2% (w/v) PEG from the 1 st day up to 2 weeks.
  • Table 22 shows all the different test samples to be prepared in 10 mM phosphate buffer at pH 7.4.
  • the 10 mM phosphate buffer was added to the appropriately weighed mass of solid active ingredients and stirred thoroughly until the active pharmaceutical agent was dissolved.
  • solid BMPA-HP powder was added to the sample formulations 1 , 2 and 3. After dissolution of the HP, the appearance was clear solution.
  • sample 2 is the best formulation, based on the Dorzolamide and Timolol solubility data.
  • surfactants such as Polysorbate 80 to HP also increases the Dorzolamide solubility by preventing the precipitation of Dorzolamide encapsulated within HP.
  • Table 23 Contents of Dorzolamide and Timolol, appearance and pH of samples at room temperature.
  • Table 24 Contents of Dorzolamide and Timolol, appearance and pH of samples at 60 °C. Tables 23 and 24 demonstrate the stability test results of Dorzolamide and Timolol over a period of 4 weeks for all the formulation samples. It is evident from the Table that sample # 1 and sample #2 are relatively stable and clear solutions after 1 month. The presence of PEG in sample # 1 could be avoided since sample #2 without PEG gives similar results.
  • Table 25 Composition of test formulations.
  • Table 26 Initial concentration of active ingredients in test samples.
  • the corneal hydration was measured based on the net wet weight and dry weight of the cornea. Typically, the % (w/w) hydrations for cornea in normal mammalian are in the range of 75-85%. Overall, there was no significant change in the % hydrations for all the test samples, and all were within the desired range, as shown in Table 27. Thus, the HP and Polysorbate 80 did not have impact on corneal hydration.
  • Figure 36 and Figure 37 reveal the corneal permeation profiles of Dorzolamide and Timolol, respectively.
  • the time dependent permeation of Dorzolamide and Timolol was examined carefully across the isolated rabbit cornea at 34 °C. From Figure 36, the Dorzolamide cumulative total amount permeated through the cornea and the total amount permeated after 3 hours was relatively higher for the test formulation containing 4% (w/v) HP and Polysorbate 80 at pH 7.4 (Test 3) compared to the same formulation at pH 5.65 (Test 2).
  • Teest 3 the test formulation containing
  • Dorzolamide cornea permeation for Test 3 is comparable to the control solution with no additives at pH 5.65 (Test 1). Notice that Test 3 contains 1 % (w/v) Dorzolamide while Test 1 contains 2% (w/v) Dorzolamide. While Test 3 contains half the Dorzolamide concentration of Test 1 , the cornea permeation profiles are similar. Test 3 could be more comfortable for the patient since it is prepared at pH 7.4 compared to the market product at pH 5.65 that can cause eye irritation. Timolol permeation profiles from Figure 37 suggest that Test 3 has significantly higher cornea permeation compared to Test 1 (control solution).
  • Timolol permeation is enhanced by the presence of hyperbranched polyester and Polysorbate 80 in Test 3 at pH 7.4 compared to Test 1 having similar aqueous solubility.
  • enhanced Timolol permeation and comparable Dorzolamide permeation to the market product are key advantages of new formulation containing HP and Polysorbate 80. From Figure 38, the total percentage permeation of Dorzolamide and Timolol after 3 hours in case of Test 3 (novel formulation) was at least 2 times higher than Test 1 (market product active ingredients).
  • the presence of HP and Polysorbate 80 increase the percentage of active ingredients (Dorzolamide and Timolol) permeated through the cornea.
  • the slopes from Figure 36 and 37 were used in order to determine the corneal permeability coefficient and partition coefficient.
  • the permeability coefficient is inversely proportional to the initial concentration of the drug in the donor solution.
  • the permeability coefficients (see Figure 39) and partition coefficients (see Figure 40) of Test 2 are relatively higher than Test 1. Notice that both Test 1 and Test 2 solutions are at pH 5.65. The result suggests the influence of HP and Polysorbate 80 to enhance the partitioning and permeations of active ingredients.
  • the permeability coefficient and partition coefficient of Test 3 is higher than Test 2 due to the pH effect. Test 3 formulation is prepared at pH 7.4 which is more conducive for permeation of non-ionic Dorzolamide and Timolol. Overall, the results clearly demonstrate the importance of using HP and Polysorbate 80 as drug carrier for a topical formulation for both Dorzolamide and Timolol.
  • HP and Polysorbate 80 promote encapsulation of Timolol and Dorzolamide, and thus enhance the partitioning of Timolol into corneal epithelium. This theory is also supported by the data in Figure 40.
  • the Timolol and Dorzolamide partition coefficient to the corneal surface for Test 3 at pH 7:4 was the highest than Test 1 and Test 2 indicating the improvement in partitioning of Timolol and Dorzolamide into lipophilic corneal membrane in presence of highly functional HP at pH 7.4 rather than pH 5.65.
  • the improved permeation in presence of HP is mainly because of improved partitioning to the epithelium.
  • an ophthalmic composition comprising a HP, which shows increased aqueous solubility of carbonic anhydrase inhibitors, such as Dorzolamide or Brinzolamide, can be provided.
  • the ophthalmic composition may also comprise a non-ionic surfactant and/or a beta-blocker.
  • the ophthalmic compositions of the present invention result in increased permeation of the active agent into the cornea. Therefore, the overall ocular bioavailability and hence the therapeutic activity of the topical ophthalmic solution containing a carbonic anhydrase inhibitor and beta blocker (active ingredients) can be increased compared to current relevant ophthalmic market products available.
  • the topical ophthalmic compositions presented in this invention provide more potent anti-glaucoma compositions that may increase patient compliance by increasing ocular bioavailability.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides an ophthalmic composition comprising a hyperbranched polyester. The ophthalmic compositions may also comprise carbonic anhydrase inhibitors, wherein the hyperbranched polyester increases the aqueous solubility of the carbonic anhydrase inhibitor, and increases corneal permeation of the active agent. The ophthalmic compositions may also comprise non-ionic surfactants, such as PEG, Polysorbate, HPMC or HEC, and beta-blockers,such as Carteolol, Levobunolol, Betaxolol, Metipranolol, Timolol or Propranolol. The concentration of the hyperbranched polyester in the ophthalmic formulation should be less than or equal to 4% (w/v) in order to avoid any cytotoxic effects on human corneal cells and thus the eye irritation.

Description

OPHTHALMIC COMPOSITION
FIELD OF THE INVENTION
The present invention relates to an ophthalmic composition comprising a hyperbranched polymer. The hyperbranched polymer of the present invention may be any hyperbranched polymer which is pharmaceutically acceptable, e.g., a hyperbranched polymer with a Polyethyleneimine, Polypropyleneimine or Polyester.
BACKGROUND OF THE INVENTION
COSOPT® and TRUSOPT® are commercially available topical ophthalmic solutions developed by Merck for treating an eye disease called glaucoma. In the case of TRUSOPT®, the active ingredient is Dorzolamide exclusively. In the case of COSOPT®, the active ingredients are Dorzolamide and Timolol (beta blocker). Dorzolamide is a carbonic anhydraze inhibitor with the aqueous solubility of 40 mg/mL at pH 4.0-5.5. It is a white to off-white, crystalline powder, which is soluble in water and slightly soluble in methanol and ethanol.
However, these formulations contain 2% (w/v) Dorzolamide, and are prepared at pH 5.65, due to the limited aqueous solubility of Dorzolamide at physiological pH. Consequently, the COSOPT® and TRUSOPT® formulations can lead to local irritation, due to the low pH. Dorzolamide has two pKa values of 6.35 and 8.5, which correspond to the protonated secondary amine group and the sulfonamide group, respectively. Dorzolamide is mainly in its hy'drophilic cationic form at pH below 6.4, and in its hydrophilic anionic form above pH 8.5.
Thus, Dorzolamide has a relatively low aqueous solubility in solutions with pH between 6.4 and 8.5, mainly because of Dorzolamide's non-ionic behavior in that physiological pH range.
AZOPT® (Brinzolamide ophthalmic suspension) 1% is a sterile, aqueous suspension of Brinzolamide, which has been formulated to be readily suspended and slow settling, following shaking. AZOPT® is developed by Alcon and contains Brinzolamide as active ingredient. The formulation has a pH of approximately 7.5 and an osmolality of 300 mOsm/kg. It is instilled for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Brinzolamide's pKa values are 5.9 (amine) and 8.4 (primary sulfonamide), allowing it to act as an acid or a base (ampholyte) depending upon the pH. It is mainly in its hydrophilic cationic form at pH below 5.9 and hydrophilic anionic form above pH 8.4. It is clear that Brinzolamide is significantly less protonated (<10%) at physiological pH. Thus, Brinzolamide has relatively low aqueous solubility in solutions with pH between 5.9 and 8.4, mainly because of Brinzolamide's nonionic (lipophilic) behavior in that pH range.
Dendritic polymers are tree-like polymers that can be classified into two main types based on their branching architecture as "perfectly branched" (dendrimers) and "imperfectly branched" (hyperbranched polymers or HP). Hyperbranched polymers are molecular constructions having a branched structure, generally around a core. Unlike dendrimers, the structure of hyperbranched polymers generally lacks symmetry, as the base units or monomers used to construct the hyperbranched polymer can be of diverse nature and their distribution is non-uniform. The branches of the polymer can be of different natures and lengths. The number of base units, or monomers, may be different depending on the different branching. While at the same time being asymmetrical, hyperbranched polymers can have: an extremely branched structure, around a core; successive generations or layers of branching; a layer of end chains. Hyperbranched polymers are generally derived from the polycondensation of one or more monomers ABX, A and B being reactive groups capable of reacting together, x being an integer greater than or equal to 2. However, other preparation processes are also possible. Hyperbranched polymers are characterized by their degree of polymerization DP=100-b, b being the percentage of non-terminal functionalities in B which have not reacted with a group A. Since the condensation is not systematic, the degree of polymerization is less than 100%. An end group T can be reacted with the hyperbranched polymer to obtain a particular functionality on the ends of chains.
Hyperbranched polymers are mainly identified by their core type and their terminal groups. Examples of a core type for a hyperbranched polymer are polyethylenimine, polypropylenimine, polyglycol, polyether, polyester, etc. A hyperbranched polymer with a polyester core may be referred to as a hyperbranched polyester. Examples of terminal or surface functional groups of hyperbranched polymers are amine, hydroxyl, carboxylic acid, a fatty acid, polyethylene glycol (PEG), polyester, etc. See U.S. Patent 6,432,423, U.S. Patent 7,097,856, and U.S. Patent Publication 2006/0204472, the contents of which are incorporated herein by reference.
Figure imgf000005_0001
Schematic showing the formation of a hyperbranched polymer from the polymerization of AB? monomers.
In contrast to the "structurally perfect" dendrimers prepared by multi-step synthesis, somewhat less perfect hyperbranched polymers can be synthesized in one-step reactions. Thus, unlike dendrimers, hyperbranched polymers are rapidly prepared with no purification steps needed for their preparation. Consequently, hyperbranched polymers are significantly less expensive than dendrimers. Thus it makes hyperbranched polymers amenable for large-scale in vivo trials and bringing highly branched polymers as candidates for drug delivery of even common drugs as ibuprofen (Kannan, R.M. et al., Biomedical Applications of Nanotechnology, 2007, John Wiley & Sons Inc., p. 105).
OBJECT OF THE INVENTION
An object of the invention is to provide an improved ophthalmic composition, with improved aqueous solubility and corneal permeation of the active agent. SUMMARY OF THE INVENTION
The present inventors have studied ophthalmic compositions comprising hyperbranched polymers. The present inventors have discovered that hyperbranched polymers are muco- adhesive polymers with a high force of bioadhesion, which provide strong electrostatic interactions between the negatively charged cornea mucin membrane and the cationic hyperbranched polymers.
The present inventors have discovered that hyperbranched polymers increase the aqueous solubility of carbonic anhydrase inhibitors such as Dorzolamide or Brinzolamide for glaucoma therapy. Additionally, the present inventors have discovered that the aqueous solubility of Dorzolamide or Brinzolamide increases linearly with an increase in the concentration of the hyperbranched polymer. Furthermore, the present inventors have discovered that hyperbranched polymers, such as Bis-MPA hyperbranched polyester with hydroxyl functional groups (2nd generation), can be safely employed up to 4% (w/v) with no cytotoxic or eye irritation, based on in vitro human corneal epithelial cell culture studies. Additionally, the present inventors have discovered that hyperbranched polymers increase the corneal permeation and partitioning of Dorzolamide and Timolol into intact cornea, and increase the partitioning of Dorzolamide and Timolol into the lipophilic cornea membrane.
Accordingly, the present invention provides:
( 1 ) An ophthalmic composition comprising a hyperbranched polymer, wherein the hyperbranched polymer comprises a terminal functional group selected from the group consisting of an amine group, a hydroxyl group, a fatty acid group, and Polyethylene Glycol (PEG).
(2) The ophthalmic composition according the above ( 1), further comprising a
carbonic anhydrase inhibitor.
(3) The ophthalmic composition according to the above (1 ) or (2), further comprising a non- ionic surfactant.
(4) The ophthalmic composition according to the above (1), wherein the average molecular weight of the hyperbranched polymer is in the range from 1 ,000 to 750,000 Daltons (Mw).
(5) The ophthalmic composition according to the above (1 ) or (2), wherein the hyperbranched polymer comprises a core selected from the group consisting of Polyethylenimine, Polypropylenimine, and polyester.
(6) The ophthalmic composition according to the above (1), wherein the pH is in the range from 3.0 to 8.0.
(7) The ophthalmic composition according to the above ( 1), wherein the concentration of the hyperbranched polyester is in the range from 0.01 % to 5% (w/v).
(8) The ophthalmic composition according to the above (2), further comprising a beta- blocker.
(9) The ophthalmic composition according to the above (2), wherein the carbonic anhydrase inhibitor is selected from the group consisting of Dorzolamide, Brinzolamide and Acetazolamide.
(10) The ophthalmic composition according to the above (3), wherein the non-ionic surfactant is selected from the group consisting of PEG, Polysorbate, Hydroxyl Propyl Methyl Cellulose (HPMC), and Hydroxy Ethyl Cellulose (HEC). (1 1) The ophthalmic composition according to the above (8), wherein the beta-blocker is selected from the group consisting of Carteolol, Levobunolol, Betaxolol, Metipranolol, Timolol and Propranolol.
(12) The ophthalmic composition according to the above (5), wherein the hyperbranched polymer core is polyester, and wherein the hyperbranched polymer comprises a hydroxyl group, a fatty acid group, and PEG as terminal functional groups.
(13) The ophthalmic composition according to the above (12), wherein the average molecular weight of the hyperbranched polymer is in the range from 1 ,000 to 12,000 Daltons (Mw).
(14) The ophthalmic composition according to the above ( 12), wherein the
concentration of the hyperbranched polymer is in the range from 0.001 % to 4% (w/v).
(15) An ophthalmic composition comprising a hyperbranched polyester, Timolol, Dorzolamide, and Polysorbate 80, wherein the hyperbranched polyester comprises a terminal functional group selected from the group consisting of polyester hydroxyl group, a fatty acid group, and PEG.
(16) An ophthalmic composition comprising a hyperbranched polyester, Timolol, Brinzolamide, and Polysorbate 80, wherein the hyperbranched polyester comprises a terminal functional group selected from the group consisting of polyester hydroxyl group, a fatty acid group, and PEG. BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the pH-solubility profile of Dorzolamide in 0.1 % (w/v) phosphate buffer.
Figure 2 shows the dependence of hyperbranched polymer concentration on the aqueous solubility of Dorzolamide in 0.1% (w/v) phosphate buffer at pH 5.65.
Figure 3 shows the dependence of hyperbranched polymer concentration on the aqueous solubility of Dorzolamide in 0.1 % (w/v) phosphate buffer at pH 7.
Figure 4 shows the effect of a combination of PEG 8000 and hyperbranched polymer (Lupasol® PS) with various concentrations on the aqueous solubility of Dorzolamide at pH 7.
Figure 5 shows the viscosity as a function of shear rate at 20 °C of different solutions in 0.1% (w/v) phosphate buffer.
Figure 6 shows the force of bioadhesion at pH 7 and shear rate of 80 s"1.
Figure 7 shows the maximum aqueous solubility of Dorzolamide at pH 5.65 and pH 7 with addition of additives in the presence of 0.5% Timolol in the aqueous solution in all cases.
Figure 8 shows the maximum Dorzolamide solubility at pH 7 with different combinations of additives in the presence of 0.5% Timolol.
Figure 9 shows the schematic of a standard side by side diffusion cell.
Figure 10 shows the mean permeation profiles (n=2) of Dorzolamide through intact rabbit corneas for a formulation containing Lupasol® PS hyperbranched polymer.
Figure 1 1 shows the mean permeation profiles (n=2) of Timolol through intact rabbit corneas for a formulation containing Lupasol® PS hyperbranched polymer.
Figure 12 shows the mean percentage total corneal permeation of Dorzolamide and Timolol after 3 hours for a formulation containing Lupasol® PS hyperbranched polymer.
Figure 13 shows the mean corneal permeability coefficients of Dorzolamide and Timolol for a formulation containing Lupasol PS hyperbranched polymer.
Figure 14 shows the mean diffusion coefficients of Dorzolamide and Timolol for permeation through intact rabbit corneas for a formulation containing Lupasol® PS hyperbranched polymer.
Figure 15 shows the mean partition coefficients of Dorzolamide and Timolol for permeation through intact rabbit corneas for a formulation containing Lupasol® PS hyperbranched polymer.
Figure 16 shows the aqueous solubility of Brinzolamide in 10 mM phosphate buffer at different pH values.
Figure 17 shows the maximum aqueous solubility of Brinzolamide at pH 7 with addition of additives in the absence and presence of 0.5% Timolol in the aqueous solution.
Figure 18 shows the mean permeation profiles of Dorzolamide (n=2) through rabbit corneas for a formulation containing Boltorn® H20 hyperbranched polymer.
Figure 19 shows the mean permeation profiles of Timolol (n=2) through rabbit corneas for a formulation containing Boltorn® H20 hyperbranched polymer.
Figure 20 shows the mean percentage total corneal permeation of Dorzolamide and Timolol after 2 hours for a formulation containing Boltorn® H20 hyperbranched polymer.
Figure 21 shows the mean corneal permeability coefficients of Dorzolamide and Timolol for a formulation containing Boltorn® H20 hyperbranched polymer.
Figure 22 shows the mean diffusion coefficients of Dorzolamide and Timolol for permeation through intact rabbit corneas for a formulation containing Boltorn® H20 hyperbranched polymer. Figure 23 shows the mean partition coefficients of Dorzolamide and Timolol for permeation through intact rabbit corneas for a formulation containing Boltorn® H20 hyperbranched polymer.
Figure 24 shows the maximum aqueous solubility of Brinzolamide at pH 7.4 with addition of Boltorn® W3000 (amphiphilic HP) in the presence of 0.5% (w/v) Timolol in the emulsion solution.
Figure 25 shows the mean permeation profiles of Dorzolamide (n=2) through intact rabbit corneas for a formulation containing Boltorn® W3000 hyperbranched polymer.
Figure 26 shows the mean permeation profiles (n=2) of Timolol through intact rabbit corneas for a formulation containing Boltorn® W3000 hyperbranched polymer.
Figure 27 shows the mean percentage total corneal permeation of Dorzolamide and Timolol after 3 hours for a formulation containing Boltorn® W3000 hyperbranched polymer.
Figure 28 shows the mean corneal permeability coefficients of Dorzolamide and Timolol for a formulation containing Boltorn® W3000 hyperbranched polymer.
Figure 29 shows the mean diffusion coefficients of Dorzolamide and Timolol for permeation through intact rabbit cornea for a formulation containing Boltorn® W3000 hyperbranched polymer.
Figure 30 shows the mean partition coefficients of Dorzolamide and Timolol for permeation through intact rabbit cornea for a formulation containing Boltorn® W3000 hyperbranched polymer.
Figure 31 shows the maximum aqueous solubility of Brinzolamide at pH 7.4 with addition of 2nd Bis-MPA hyperbranched polyester or 3rd Bis-MPA hyperbranched polyester in the presence of 0.5% (w/v) Timolol. Figure 32 shows the in vitro human corneal epithelium cell viability of different concentrations of hyperbranched polyesters (hydroxyl groups generation 2 and 3), and AZOPT®.
Figure 33 shows the cytotoxicity of Bis-MPA hyperbranched polyester for different concentrations.
Figure 34 shows the solubility and stability of Dorzolamide at pH 7.4 with addition of Bis-MPA hyperbranched polyester and non-ionic surfactants in the presence of 0.5% (w/v) Timolol.
Figure 35 shows the maximum aqueous solubility of Dorzolamide at pH 7.4 with addition of different additives in the presence of 0.5% (w/v) Timolol.
Figure 36 shows intact cornea permeation profile of Dorzolamide for formulation containing Bis MPA hyperbranched polyester (2nd generation).
Figure 37 shows intact cornea permeation profile of Timolol for formulation containing Bis MPA hyperbranched polyester (2nd generation).
Figure 38 shows the mean percentage total corneal permeation of Dorzolamide and Timolol after 3 hours for formulation containing Bis MPA hyperbranched polyester (2nd generation).
Figure 39 shows the permeability coefficients of Dorzolamide and Timolol for formulation containing Bis MPA hyperbranched polyester (2nd generation).
Figure 40 shows the partition coefficients of Dorzolamide and Timolol for formulation containing Bis MPA hyperbranched polyester (2nd generation).
DETAILED DESCRIPTION OF THE INVENTION
The compositions of the present invention are topically administratable therapeutic compositions for treatment of conditions of the eye. Such conditions of the eye include glaucoma, and ocular diseases such as cataract, conjunctivitis, infection, inflammation or retinopathy.
A detailed description of the invention is provided below.
The present invention includes an ophthalmic composition comprising a hyperbranched polymer.
The hyperbranched polymer according to the present invention may be any hyperbranched polymer which is pharmaceutically acceptable, e.g., a hyperbranched polymer with a Polyethyleneimine, Polypropylenimine or a polyester core. The molecular weight of the hyperbranched polymer in the ophthalmic compositions of the present invention is in the range of from 1 ,000 to 750,000 Daltons, preferably in the range of 1 ,000 to 12,000 Daltons. The molecular weight is weight average molecular weight measured by dynamic light scattering. The concentration of the hyperbranched polymer in the ophthalmic compositions of the present invention is in the range from 0.001% to 10% (w/v), preferably in the range from 0.001% to 5% (w/v), more preferably in the range from 0.001% to 4% (w/v), more preferably in the range from 0.01% to 4% (w/v), more preferably in the range of 0.01 % to 3% (w/v).
The ophthalmic composition discussed above may also comprise a carbonic anhydrase inhibitor. Carbonic anhydrase inhibitors are a class of pharmaceuticals that suppress the activity of carbonic anhydrase, and are known to be useful as anti-glaucoma agents. Examples of carbonic anhydrase inhibitors which may be present in the ophthalmic compositions of the present invention are Dorzolamide, Brinzolamide or Acetazolamide. The ophthalmic composition discussed above may also comprise a non-ionic surfactant. The non-ionic surfactant may be any non-ionic surfactant which is known as a pharmaceutically acceptable additive, for example, Polysorbate 80, PEG 8000, HPMC or HEC.
The ophthalmic compositions of the present invention are advantageously used after being adjusted to a pH range which is conventionally adopted for topical application to the eye, and is normally employed after being adjusted to a pH of 3 to 8, preferably a pH of 5 to 8. For the pH adjustment, hydrochloric acid, acetic acid, sodium hydroxide, etc. can be used.
The ophthalmic compositions of the present invention may also comprise a beta-blocker. Beta-blockers are known to reduce the pressure within the eye (the intraocular pressure), and thus, are used to lessen the risk of damage to the optic nerve and loss of vision in patients with glaucoma. The beta-blocker in the ophthalmic compositions of the present invention may be any beta-blocker which is known as acceptable in ophthalmic compositions, such as Carteolol, Levobunolol, Betaxolol, Metipranolol, Timolol and Propranolol.
A first specific embodiment of the present invention is an ophthalmic composition comprising a hyperbranched polymer, Timolol, Dorzolamide, PEG 8000 and Polysorbate 80.
Such compositions preferably comprise about 0.001 % to 10% (w/v) of the hyperbranched polymer, most preferably about 1 to 5% (w/v), and 0.05 to 1 % (w/v) of Timolol, most preferably about 0.5% (w/v), and about 0.05 to 5% (w/v) of Dorzolamide, most preferably about 0.5 to 2% (w/v), and about 0.05 to 5% (w/v) of PEG 8000, most preferably about 0.5 to 4% (w/v), and about 0.05 to 5% (w/v) of Polysorbate 80, most preferably about 0.5 to 4% (w/v), and are to be administered once or twice a day to each affected eye.
A second specific embodiment of the present invention is an ophthalmic composition comprising a hyperbranched polymer, Timolol, Brinzolamide, PEG 8000 and Polysorbate 80. Such compositions preferably comprise about 0.001 % to 10% (w/v) of the hyperbranched polymer, most preferably about 1 to 5% (w/v), and 0.05 to 1 % (w/v) of Timolol, most preferably about 0.5% (w/v), and about 0.05 to 5% (w/v) of Brinzolamide, most preferably about 0.5 to 2% (w/v), and about 0.05 to 5% (w/v) of PEG 8000, most preferably about 0.5 to 4% (w/v), and about 0.05 to 5% (w/v) of Polysorbate 80, most preferably about 0.5 to 4% (w/v), and are to be administered once or twice a day to each affected eye.
A third specific embodiment of the present invention is an ophthalmic composition comprising a hyperbranched polyester, Timolol, Dorzolamide, PEG 8000 and Polysorbate 80.
Such compositions preferably comprise about 0.1% to 10% (w/v) of the hyperbranched polyester, most preferably about 1 to 5% (w/v), and 0.05 to 1% (w/v) of Timolol, most preferably about 0.5% (w/v), and about 0.05 to 5% (w/v) of Dorzolamide, most preferably about 0.5 to 2% (w/v), and about 0.05 to 5% (w/v) of PEG 8000, most preferably about 0.5 to 4% (w/v), and about 0.05 to 5% (w/v) of Polysorbate 80, most preferably about 0.5 to 4% (w/v), and are to be administered once or twice a day to each affected eye.
A fourth specific embodiment of the present invention is an ophthalmic composition comprising a hyperbranched polyester, Timolol, Brinzolamide, PEG 8000 and PEG 8000.
Such compositions preferably comprise about 0.1% to 10% (w/v) of the hyperbranched polyester, most preferably about 1 to 5% (w/v), and 0.05 to 1 % (w/v) of Timolol, most preferably about 0.5% (w/v), and about 0.05 to 5% (w/v) of Brinzolamide, most preferably about 0.5 to 2% (w/v), and about 0.05 to 5% (w/v) of PEG 8000, most preferably about 0.5 to 4% (w/v), and about 0.05 to 5% (w/v) of Polysorbate 80, most preferably about 0.5 to 4% (w/v), and are to be administered once or twice a day to each affected eye.
The ophthalmic compositions according to the present invention may comprise a pharmacologically acceptable carrier, excipient or diluent which is known per se and may be formulated by a method known per se for preparing ophthalmic compositions. The ophthalmic compositions of the present invention may be provided in any pharmaceutical dosage form that is conventionally used as an ophthalmic preparation, e.g., eye drops, emulsions, and eye ointments.
The eye drop formulation may, for example, be an aqueous formulation, such as ophthalmic solution which is clear solution, ophthalmic suspension, ophthalmic emulsion, as well as non-aqueous formulations, such as non-aqueous ophthalmic solution and non-aqueous ophthalmic suspension.
The ophthalmic solution formulation may contain various additives incorporated ordinarily, such as buffering agents (e.g., phosphate buffers, borate buffers, citrate buffers, tartarate buffers, .acetate buffers, amino acids, Sodium acetate, Sodium citrate and the like), isotonicities (e.g., saccharides such as sorbitol, glucose and mannitol, polyhydric alcohols such as Glycerin, concentrated Glycerin, PEG and Propylene glycol, salts such as Sodium chloride), preservatives or antiseptics (e.g., Benzalkonium chloride, Benzethonium chloride, P- oxybenzoates such as Methyl p-oxybenzoate or Ethyl p-oxybenzoate, Benzyl alcohol, Phenethyl alcohol, Sorbic acid or its salt, Thimerosal, Chlorobutanol and the like), solubilizing aids or stabilizing agents (e.g., cyclodextrins and their derivative, water-soluble polymers such as polyvinyl pyrrolidone, surfactants such as tyloxapol, pH modifiers (e.g., Hydrochloric acid, Acetic acid, Phosphoric acid, Sodium hydroxide, Potassium hydroxide, Ammonium hydroxide and the like), thickening agents (e.g., HEC, Hydroxypropyl cellulose, Methyl cellulose, HPMC, Carboxymethyl cellulose and their salts), chelating agents (e.g., Sodium edetate, Sodium citrate, condensed Sodium phosphate) and the like. The eye drop formulation in the form of an aqueous suspension may also contain suspending agents (e.g., Polyvinyl pyrrolidone, Glycerin monostearate) and dispersing agents (e.g., surfactants such as Tyloxapol, ionic polymers such as Sodium alginate) in addition to the additives listed above, whereby ensuring that the eye drop formulation is a further uniform microparticulate and satisfactorily dispersed aqueous suspension.
The eye drop formulation in the form of an aqueous suspension preferably contains Sodium citrate or Sodium acetate as a buffering agent, concentrated Glycerin and/or Propylene glycol as an isotonicity and Polyvinyl pyrrolidone as a suspending agent. A preferred dispersing agent is a surfactant and/or Sodium alginate. Such surfactant is preferably Tyloxapol.
The ophthalmic composition of the present invention may be administered to a mammal which is or may be suffering from an ophthalmic disease, such as glaucoma (e.g., a human, rabbit, dog, cat, cattle, horse, monkey).
While the administration route and the dose may vary depending on a symptom, age and body weight of a subject, the concentration of the active agent in the ophthalmic composition of the present invention is about 0.001 to 5 (w/v) %, preferably about 0.01 to 3 (w/v) % contained in an aqueous eye drop formulation when given to an adult, and is given preferably 1 to 8 times a day with a single dose being one to several drops.
Unless the intended purpose of use is affected adversely, the ophthalmic compositions of the present invention may contain or may be used together with other appropriate pharmacologically effective substances, for example, steroidal anti-inflammatory agents (Dexamethasone, Prednisolone, Loteprednolm Fluorometholone, Fluocinolone and the like), non-steroidal anti-inflammatory agents (Diclofenac sodium, Pranoprofen, Bromfenac, Ketorolac tromethamine, Napafenac, Flurbiprofen Sodium and the like), antiallergic agents (Tranilast, Ketotifen fumarate, Olopatadine hydrochloride, Sodium Cromoglicate, Potassium Pemirolast, Sodium Nedocromil and the like), antihistamic agents (Epinastine hydrochloride, Azelastine hydrochloride, Azalastine hydrochrilidem, Diphenhydramine hydrochloride and the like), glaucoma-treating agents (Pilocarpine hydrochloride, Physostigmine salicylate, Timolol, Isopropylunoprostone, Latanoprost, Betaxolol hydrochloride, Apraclonidine, Brimonidine Tartrate, Carbacol, Dipivefrin, Bimatoprost, Travoprost, Brimonidine tartrate and the like), antibiotics (Azithromycin, Gentamycin sulfate, Fradiomycin sulfate, Tobramycin, Sulbenicillin, Cefmenoxime, Erythromycin, Colistin, Oxytetracycline, Polymyxin B, Chloramphenicol, Micronomicin, Dibekacin, Sisomicin and the like), antibacterial agents (Sulfamethizole, Sulfamethoxazole, Ofloxacin, Norfloxacin, Lomefloxacin hydrochloride, Moxifloxacin hydrochloride, Enoxacin, Ciprofloxacin hydrochloride, Cinoxacin, Sparfloxacin, Tosufloxacin tosylate, Nalidixic acid, Pipemidic acid Trihydrate, Pipemidic acid, Fleroxacin, Levofloxacin, Gatifloxacin and the like), and antiviral agents (Idoxuridine, Acyclovir and the like), and antimycotic agents (Pimaricin, Fluconazole, Miconazole, Amphotericin B, Flucytosine, Itraconazole and the like), anti VEGF antibody (Pegaptanib and the like).
The ophthalmic compositions of the present invention may be produced by dissolving or dispersing the active agent(s), hyperbranched polymer and optionally the non-ionic surfactant in a solution appropriately containing pharmaceutically acceptable additives, such as isotonicity agents, buffers, preservatives, suspending agents, thickeners, stabilizers, pH adjusting agents, and the like.
The present inventors hereby incorporate by reference prior filed U.S. Application No. 12/774,419, in its entirety. The present invention is further illustrated in detail by the following Experimental Examples. These Experimental Examples are merely illustrative, and are not intended to limit the scope of the present invention.
EXPERIMENTAL EXAMPLE 1
pH-solubility profile of Dorzolamide in aqueous solution containing different concentrations of Hyperbranched Polymer (HP) (Lupasol® G20, Lupasol® G 35, Lupasol® PS) and PEG.
Methods
Suspensions of Dorzolamide hydrochloride in 0.1% (w/v) phosphate buffer solution at pH 5.5, pH 6, pH 6.5, pH 7, pH 7, pH 8 and pH 8.5 were prepared. Similar suspensions were also prepared in aqueous solution containing different concentrations of different HP and PEG with a molecular weight of 8000. A combination of Polysorbate 80 and PEG 8000 was also attempted. The pH was measured accurately with micro-pH electrode (Thermo Scientific). The desired pH was adjusted using either 1 M NaOH or 1 M HC1. The suspension solutions were first stirred for 10 min at room temperature (with heating up to 60 °C for 5 minutes). After allowing the suspensions to equilibrate at room temperature for an additional 30 minutes, the suspension solutions were then sonicated for 10 minutes and finally filtered through 0.45 μπι syringe filters. The filtrates were analyzed for Dorzolamide concentration using UPLC. Dorzolamide detection was performed using: a gradient 1 % (v/v) Triethylamine (TEA) in watenacetonitrile method, performed at room temperature, with the flow rate of 0.7 mL/min, at 254 nm wavelength and 10 injection volume, on BEH C I 8 1.7 μηι, 2.1 x 50 mm column. A calibration curve was prepared to find Dorzolamide concentration. The properties of polymers used are listed in Table 1. Polymer name Viscosity (cP) Molecular pKa Solid content (% w/v) weight
Lupasol® G 20 200-500 1300 7-10 >98%
Lupasol® G 35 250-650 2000 7-10 48-52%
Lupasol® PS 1000-2500 750,000 7-10 33%
Table 1 : Properties of HPs in EXPERIMENTAL EXAMPLE 1 .
Results and Discussion
Figure 1 demonstrates that the aqueous solubility of Dorzolamide decreases as the pH increases from 5.65, and reaches a bottom at pH 7. Since COSOPT® is formulated at pH 5.65,
Dorzolamide solubility in 0.1% (w/v) phosphate buffer was quantified in the presence of different HP of different concentrations at pH 5.65. The result is presented in Figure 2. The solubility of Dorzolamide increased at pH 5.65 with the increase in concentrations of HP from
0.1 % to 1 % (w/v). Similarly at pH 7, as shown in the bar graph of Figure 3, Dorzolamide solubility increased linearly with the increase in concentration of HP from 0.1 % (w/v) to 4%
(w/v).
As shown in Figure 4, combinations of various concentrations of PEG 8000 and 0.5% and 1 % (w/v) of HP (Lupasol® PS) were applied at pH 7. It is clear from Figure 4 that 2% (w/v) solubility of Dorzolamide (similar to COSOPT®) in phosphate buffer at pH 7 can be achieved by using about 20% PEG 8000 and 0.5% of Lupasol® PS, or 17% of PEG 8000 and 1 % Lupasol® PS.
Conclusion
The present inventors discovered that the aqueous solubility of Dorzolamide increased with an increase in the concentration of HP and PEG. In the case of PEG, the solubility also increased linearly with an increase in the molecular weight of the PEG. Further, the Polysorbate 80 assists in dispersing the Dorzolamide molecules and inhibits the precipitation in water in presence of PEG.
From these results, it is concluded that HP significantly enhances the solubility of Dorzolamide. Additionally, hydrophilic polyethylene glycol was discovered to be a Dorzolamide solubility enhancer. The results demonstrate the advantages of using hyperbranched polymers and PEG as Dorzolamide solubility enhancing additives at pH values closer to physiological pH.
EXPERIMENTAL EXAMPLE 2
A simple rheological method for the in vitro assessment of mucin-hyperbranched polymer bioadhesive bond strength.
A simple viscometric method was adopted to quantify the mucin-polymer bioadhesive bond strength. In order to determine the muco-adhesive properties of commercially available HP called Lupasol® PS, the force of bioadhesion was calculated for different concentrations of HP with porcine gastric mucin at pH 7 in comparison with the market product COSOPT®. Porcine gastric mucin was used as a model mucin. However, since all mucins appear to share general physical, structural, and rheological properties, it is believed that porcine gastric mucin is a satisfactory model for primary evaluation of bioadhesive materials.
Methods
Brookfield Rotational L VDVE viscometer was employed for all measurements. Spindle with code number 18 was used for all viscosity measurements. A factor of 1 .32 was used to convert rpm to shear rate (s 1) as per the manual. A solution of 15% (w/v) of gastric mucin was prepared in 0.1% (w/v) phosphate buffer at pH 7. The individual viscosities 0.5% (w/v) and 1 % (w/v) of Lupasol PS in phosphate buffer solution were measured. The viscosities of 15% mucin in phosphate buffer were also measured. The viscosity was measured at 20 °C at different shear rates D from 2.6 to 80 s"1. (Hassan, E. et al., Pharm Res. 5 (1990) 491) Five samples of 10 mL each were prepared with different concentrations of Lupasol® PS, PEG and with and without 15% (w/v) gastric mucin in 0.1 % (w/v) phosphate buffer at pH 7.
Figure imgf000022_0001
Table 2: Contents (% w/v) of Test Samples.
Sample #7 is the original COSOPT market product. The viscosity at 20 °C was measured at different shear rates. The force of bioadhesion was calculated using equations (1 ) and (2), discussed above.
The force of bioadhesion (F) was calculated as per the following equation (1 ):
F= T|bo ( 1 ) where σ is the rate of shear per second, and r|b is based on experimental measured values as per the following equation (2):
Tib = ηι - r|m - ηΡ (2) where r|t is the viscosity coefficient of the system, and r m and ηρ are the individual viscosity coefficients of mucin and the bioadhesive polymer (e.g., HP and PEG 8000), respectively. For equations (1) and (2) to be valid, t|t, r|m and ηρ should be measured at the same concentration, temperature, time, and rate of shear. The bioadhesive phenomenon plays a dominant role in the contact time of aqueous tear that substitute in the precorneal area.
Results & Discussion
As shown in Figure 5, the low concentrations of HP in phosphate buffer have relatively less viscosity compared to COSOPT® (Sample #7) and mucin (Sample #1 ). The viscosities of HP (0.5%, Sample #2 and 1 %, Sample #4) are relatively close to water at high shear rates. In addition, at high shear rates the difference between the viscosities of 0.5% (w/v) HP and 1% (w/v) are negligible. The result clearly suggests the advantage of using HP as an additive with rheological properties that may be very compatible for topical ophthalmic solutions since the addition of HP to a formulation may not change the rheological properties of final formulation.
The force of bioadhesion was quantified based on the data available from Figure 5 at shear rate of 80 s"1. High shear rate was chosen since the polymers typically exhibit bioadhesive properties at high shear rates (close to 100 s"1).
As shown in Figure 6, the bioadhesive bond strength of low concentrations (0.5% (w/v) and 1 % (w/v)) of HP-mucin system is almost more than two times to that of COSOPT®-mucin system. The addition of 2% (w/v) PEG did not change the force of bioadhesion of 1% (w/v) HP- mucin system, suggesting that 2% PEG may not have influence on force of bioadhesion caused by the HP at pH 7. Overall, the results shown in Figure 6 indicate that the bioadhesive strengths of low concentrations of HPs are relatively significant compared to the polymers present in COSOPT® formulation. The bioadhesive phenomenon may be very conducive for increasing the ocular bioavailability of the drug. Conclusion
In conclusion, data generated by the viscometric assessment method of bioadhesion suggests that the hyperbranched polymers are bio-adhesive additive materials that could strongly interact with ocular mucin. These bioadhesive forces between mucin and HP could eventually lead to enhancement of the ocular bioavailability of the drug.
EXPERIMENTAL EXAMPLE 3
Aqueous solubility of Dorzolamide in the presence of Timolol for a novel formulation containing HP (Lupasol® PS) and Polysorbate 80 or a combination of PEG and Polysorbate 80 at pH 5.65 and pH 7.
Methods
A suspension of Dorzolamide hydrochloride and 0.5% (w/v) Timolol in citrate buffer solution at pH 5.65 was prepared (Control sample). A similar suspension was also prepared in aqueous solution containing 2% (w/v) of HP in citrate buffer of pH 3. The final pH was adjusted to 5.65 with 1 M NaOH after addition of HP (sample 1 ). The combination of different molecular weight PEG and Polysorbate 80 at pH 5.65 as per Table 3 were also attempted. Table 3 shows all the different test samples suspensions to be prepared in 10 mM citrate buffer.
Figure imgf000025_0001
Table 3: Different Test formulations prepared at pH 5.65 in citrate buffer, and at pH 7 in phosphate buffer.
Similarly, the formulations were again prepared in 10 mM phosphate buffer (Table 3) for the formulations to be tested for Dorzolamide solubility at pH 7 in phosphate buffer rather than citrate buffer. The suspension solutions were first stirred for 10 min at room temperature (with heating up to 60 °C for 5 minutes). After allowing the suspensions to equilibrate at room temperature for an additional 30 minutes, the suspension solutions were then sonicated for 10 minutes and finally filtered through 0.45 μπι syringe filters. The filtrates were analyzed for Dorzolamide and Timolol concentration using UPLC with the same condition as EXPERIMENTAL EXAMPLE 1 .
24
/ Results and Discussion
In this experiment, the present inventors used HP, PEG, and Polysorbate 80 as solubility enhancer additives. Different combinations were attempted at pH 5.65 and pH 7. As shown in Figure 7, the solubility of Dorzolamide was shown to increase with the addition of additives, compared to the control sample without additives, at pH 5.65 and pH 7 in the presence of Timolol. At pH 5.65, in all cases the solubility of Dorzolamide was above 2%, and therefore the addition of HP or PEG and Polysorbate 80 combination increased solubility of Dorzolamide in the presence of Timolol.
While the market COSOPT® product has 2% (w/v) Dorzolamide at pH 5.65, the enhancement of solubility at pH 5.65 with more than 2% (w/v) Dorzolamide solubility by addition of HP or PEG will not have useful contribution to efficacy enhancement of drug by increasing the dosage. Thus, the solubility data at pH 7 is more vital, where Dorzolamide has poor solubility (less than 0.5% w/v solubility) in 10 mM phosphate buffer. It was also noted that the solubility of Timolol in the formulation samples (each containing exactly 0.5% w/v Timolol) did not change at pH 5.65 and pH 7 with the addition of additives. Since COSOPT® is formulated at pH 5.65, the Dorzolamide solubility in the presence of Timolol was quantified by the addition of different HP of different concentrations at pH 5.65 to the formulation sample. The result is presented in Figure 7. As shown in the bar graph, Dorzolamide solubility increases linearly with the increases in concentration of HP from 0.5% to 2% (w/v) at pH 5.65 and pH 7. However, the impact of HP to solubility enhancement of Dorzolamide is more pronounced at pH 5.65 than pH 7. As shown in Figure 8, the addition of Polysorbate 80 to HP increases Dorzolamide solubility. The improvement in aqueous solubility of Dorzolamide in the presence of Timolol was significant with the additions of a HP or a combination of PEG and Polysorbate 80 at pH 5.65. In this case, the Polysorbate 80 helped in dispersing Dorzolamide molecules and inhibited the precipitation in water in the presence of PEG. A combination of HP and Polysorbate 80 was the best combination for enhancement of Dorzolamide solubility in presence of Timolol at pH 7. From the results, it can be concluded that HP and Polysorbate 80 significantly enhance the solubility of Dorzolamide in the presence of Timolol at pH 7. Hydrophilic PEG also turned out to be Dorzolamide solubility enhancer. Furthermore, a combination of low concentrations of Polysorbate 80 and PEG 8000 also proved to be a very useful additive for enhancement of solubility of Dorzolamide. Overall, a formulation at pH 7 with optimized concentration of HP and Polysorbate could be very useful for increasing the ocular bioavailability.
Conclusion
The results clearly indicate the advantages of using HP and Polysorbate 80 as Dorzolamide solubility enhancing additives at pH values closer to physiological pH that are more conducive for penetration of close to 1 % (w/v) Dorzolamide through cornea membrane. Polysorbate 80 also proved to be an effective emulsifier, suppressing the precipitation of poorly soluble Dorzolamide at pH 7 in the presence of a HP.
EXPERIMENTAL EXAMPLE 4
In vitro corneal permeation study of Dorzolamide and Timolol for novel topical formulations containing HP (Lupasol® PS) and Polysorbate 80. In vitro experiments on the corneal permeation of Dorzolamide and Timolol (active ingredients of COSOPT®) were carried out to investigate the effect of the addition of 0.5% (w/v) HP, or the addition of 0.5% (w/v) HP and 1 % (w/v) Polysorbate 80, in comparison to the original market topical formulation (only active ingredients) at pH 5.65.
Materials and Methods
Experimental Method
1. Formulation Preparation: The following three solutions in 10 mM citrate buffer were formulated for examining the in vitro corneal permeation of Dorzolamide and Timolol, as well as determining the corneal hydrolysis effect.
Figure imgf000028_0001
The samples were filtered by 0.45 μπι filter syringe. The initial concentration of both the samples was determined by UPLC analysis. From the experimental data, the following inferences were made:
a) HP exclusively (from Test 1 and Test 2 data comparison).
b) Polysorbate 80 (Test 2 & Test 3 comparison) significance on cornea permeation. c) HP + Polysorbate 80 combination significance (from Test 1 , Test 2, Test 3 data comparison).
2. In vitro rabbit corneal permeation experiment Composition Chemical Formula [g/100mLl
Calcium chloride CaCl2 0.0132
Potassium chloride C1 0.04
Magnesium sulfate MgS04-7H20 0.02
Sodium dihydrogen NaH2P04-2H20 0.0187
phosphate dehydrate
Sodium chloride NaCl 0.787
Glucose Glucose 0.1
Sodium hydroxide NaOH q.s.
Water Purified Water q.s
PH PH 7.2
Table 4: Composition of receptor solution for in vitro cornea permeation experiment.
Three male rabbits (New Zealand) weighing 3-4 pounds. The age of the rabbits was 1 1 - 12 weeks. Immediately after sacrifice by an overdose of carbon dioxide gas, the eyes were enucleated, saline washed, and the corneas were separated for the use in permeation experiments. Each cornea was rinsed with freshly prepared receptor solution (Table 4) to remove excess stain. The six intact and fresh corneas were fixed between clamped donor and receptor compartments of an all glass side-by-side diffusion cell in such a way that its epithelial surface faces the donor compartment. Figure 9 shows the schematic of a simple diffusion cell used in this experiment.
The corneal area available for permeation was 0.21 1 cm2. The receptor compartment was filled with freshly prepared receptor solution at pH 7.2, as per the composition described in Table 4. An aliquot (5 mL) of sample # 1 was placed on the two intact corneas, and the opening of the donor cells was sealed with a glass cover slip. After 10 minutes of applying sample # 1 , an aliquot (5 mL) of sample #2 was applied on the next two intact corneas. Again, after 10 minutes, sample #3 aliquot (5 mL) was applied on the remaining two intact corneas. The receptor fluid (5 mL in each receptor cell) was kept at constant temperature of 34 °C using constant stirring through water jacket in all the six cases. At predetermined time intervals of 10, 20, 40, 60, 80, 100, 120, 140, 160, and 1 80 minutes, 200 μL· samples were withdrawn from the receptor solution. Thereafter, the same amount of the phosphate buffer solution was added to the receptor cell. The drug concentrations were assayed by UPLC.
3. Analysis
The Dorzolamide and Timolol maleate detection conditions were a gradient 1 % (v/v) Triethylamine (TEA) in water: acetonitrile method, performed at room temperature, with the flow rate of 0.7 mL/min, at 254 nm and 298 nm wavelength and 1 μί injection volume, on BEH C 18 1 .7 μπι, 2.1 x 50 mm column.
4. Corneal permeation parameters calculation
At the end of the experiment, each cornea (free from adhering sclera) was weighed after soaking in de-ionized water. The wet cornea was dried overnight in oven, and reweighed. From the difference of weights, corneal hydration was calculated. The final results of drug permeation were expressed as cumulative amount permeated (Q). The parameters that were calculated are as follows:
Conc.( t, ) x Cell volume (itiL) + Co«c.(/,_, ) x 02{samplingvo lume(mL))
Cumulative amount permeated (Q, ng/cm 2 ) (tj ) =
Effective area(cm 2 ) = sampling number (1-10), Cone (to) = 0 dQ/dt [ng/cm2/min] Slope of cumulative amount curve
td [min] Intercept on the time axis
Diffusion coefficient (D) [cm2/sec]
6 x td x 60
Partition Coefficient (K) [-]
dt D. x Cd 60 h [cm] Thickness of cornea: 0.04 [cm]
Cd [ng/mL] Initial drug concentration in donor solution Results and Discussion
The initial concentrations of Dorzolamide and Timolol determined by UPLC are given in Table 5.
Figure imgf000031_0001
The corneal hydration was measured based on the net wet weight and dry weight of cornea. Typically, the % (w/w) hydrations for cornea in normal mammalian are in the range of 75-80%. Overall, there was no significant change in the % hydrations for all the test samples, and they were within the desired range in all the cases. Thus, the HP or Polysorbate 80 did not have impact on corneal hydration.
Figure imgf000031_0002
Figures 10 and 11 reveal the corneal permeation profiles of Dorzolamide and Timolol, respectively. The time dependent permeation of Dorzolamide and Timolol was carefully examined across the isolated rabbit cornea at 34 °C. The Dorzolamide cumulative total amount permeated through the cornea, and the total amount permeated after 3 hours was relatively higher for the test formulation containing 0.5% (w/v) HP compared to the control sample with no additives. Furthermore, the addition of Polysorbate 80 along with HP enhanced the corneal permeation with more amount of Dorzolamide permeated than the formulation containing only HP. Overall, the addition of 0.5% (w/v) HP and 1 % (w/v) Polysorbate 80 enhanced the corneal permeation rate of Dorzolamide and Timolol by about 25-30%. A similar trend was also observed for Timolol (Figure 1 1). Thus, the combination of HP and Polysorbate 80 improved the corneal penetration of active ingredients.
Figure 12 shows the percentage total permeation of Dorzolamide and Timolol. Clearly, the presence of HP and Polysorbate 80 increased the percentage of active ingredients (Dorzolamide and Timolol) permeated through the cornea. It should be noted that all test formulations had similar initial concentrations in case of Dorzolamide and Timolol (less than 10% change). Thus, it was easy to determine the influence of each additive under similar pH conditions. In comparing test 2 with test 1 , the significance of using HP as an additive is clearly demonstrated.
Figure 13 shows the corneal permeability coefficients of Dorzolamide and Timolol. The permeability coefficient was inversely proportional to the initial concentration of the drug in the donor solution. In the case of Dorzolamide, the permeability coefficients for test 2 and test 3 were higher, suggesting that Dorzolamide in the presence of 0.5% HP has enhanced corneal permeability rate compared to pH 5.65 control formulation (Test 1 ) containing no HP. Test 3 had relatively higher corneal permeability than Test 2, thereby indicating the influence of Polysorbate 80. The Polysorbate 80 may possibly act as a viscosity enhancer, thereby increasing the bioavailability of Dorzolamide and Timolol for corneal permeation. Overall, the data from Figure 13 clearly indicates that the permeability coefficients of Timolol and Dorzolamide were higher for formulation tests 2 and 3 containing HP, and HP & Polysorbate 80, respectively, in comparison to the control test 1 without HP at pH 5.65 (similar to COSOPT® active ingredient formulation).
The diffusion coefficient of Dorzolamide and Timolol, which is inversely proportional to the lag time, did not change significantly by the addition of HP and Polysorbate 80 (see Figure 14). Thus, HP and Polysorbate 80 do not have any impact on the corneal surface. If the diffusion coefficient would have increased or decreased significantly, it would indicate the change in corneal surface properties. Since the diffusion coefficient is the inherent property of drug compound, it should not change with the addition of additives.
HP promotes encapsulation of Timolol and Dorzolamide, and thus enhances the partitioning of Timolol into corneal epithelium. This theory is also supported by the data in Figure 15. The Timolol and Dorzolamide partition coefficient to the corneal surface for Test 3 is higher than Test 1 , indicating the improvement in partitioning of Timolol and Dorzolamide into lipophilic corneal membrane in presence of 0.5% (w/v) highly functional HP. Thus, the improved permeation in the presence of HP is mainly because of improved portioning to the epithelium. The partitioning could be further enhanced by increasing the concentration of HP in the formulation solution. HP enhances corneal permeation mainly because a) molecular encapsulation within the branched structures of highly functional Polyethyleneimine, b) electrostatic interactions between the drug molecules and ionic functional amine groups of HP, and c) the muco-adhesive behavior of charged HP. The addition of 0.5% (w/v) HP and 1 % (w/v) Polysorbate 80 enhanced the corneal permeation rate of Dorzolamide and Timolol by about 25-30%. The presence of HP increased the partitioning of Dorzolamide and Timolol at pH 5.65 into the corneal membrane. There was insignificant change in the corneal diffusion rate and corneal hydration rate by the addition of HP and Polysorbate 80, suggesting that these additives did not have a harmful impact on the cornea surface. The corneal permeability coefficients of Dorzolamide and Timolol were relatively higher in the presence of HP, suggesting the significance of HP as an effective drug carrier additive. Thus, the present inventors discovered a novel formulation with enhanced corneal permeation compared to the current market product. The corneal permeation could be further enhanced by increasing the concentration of HP.
Conclusion
The cumulative amount permeated of Dorzolamide and Timolol at pH 5.65 in the presence of additives such as HP was relatively high, compared to the control formulation with no additives (COSOPT® active ingredients formulation). The 0.5% (w/v) HP and 1 % (w/v) Polysorbate 80 addition to the formulation enhanced the corneal permeation rate of Dorzolamide and Timolol by about 25-30%. The partitioning of active ingredients into the corneal epithelium increases in presence of HP. Thus, the combination of HP and Polysorbate 80 could be very effective for increasing the ocular bioavailability of COSOPT® active ingredients.
EXPERIMENTAL EXAMPLE 5
Solubility enhancement of Brinzolamide in aqueous solution containing HP (Lupasol® PS) or a combination of HP and Polysorbate 80, or PEG and Polysorbate 80 combinations at pH 7 in phosphate buffer.
The aqueous solubility of Brinzolamide in the presence of Timolol at pH 7 in 10 mM phosphate buffer was studied.
Methods
Figure imgf000035_0001
Table 7: Different Test formulations prepared in phosphate buffer at pH 7.
A suspension of Brinzolamide in phosphate buffer containing 1 % (w/v) was prepared for the control sample. Similar suspensions containing excess of Brinzolamide (> 1 % (w/v)) were also prepared in aqueous solution (10 mM phosphate buffer) containing different combinations of HP, PEG and Polysorbate 80 as per Table 7 above. The final pH was adjusted to 7 with 1 M NaOH. The suspension solutions were first stirred for 10 min at room temperature (with heating up to 60 °C for 5 minutes). After allowing the suspensions to equilibrate at room temperature for additional 30 minutes, the suspension solutions were then sonicated for 10 min and finally filtered through 0.45 μιη syringe filters. The filtrates were analyzed for Brinzolamide concentration using UPLC with the same condition as EXPERIMENTAL EXAMPLE 1.
Results and Discussion
Figure 16 shows the Brinzolamide solubility in 10 mM phosphate buffer at different pH values. It is clear that the aqueous solubility of Brinzolamide decreases as the pH increases from 4 towards 7. The solubility of Brinzolamide is least at pH 7, consistent with the complete non- ionic behavior at pH 7. As % ionization of Brinzolamide increases with the increase in pH from 8.4 towards 10, the solubility increases steeply consistent with the anionic nature of Brinzolamide in that pH range. The solubility properties are very similar to Dorzolamide. Therefore, it is important to develop a lipophilic Brinzolamide drug with enhanced solubility close to pH 7.4 (pH of tear fluid is 7.44) in order to enhance ocular bioavailability and to decrease eye irritation appearance of Brinzolamide.
In this study, the present inventors used HP, PEG, and Polysorbate 80 as solubility enhancer additives. Different combinations were attempted at pH 7. In Figure 17, the solubility of Brinzolamide is shown to increase with the addition of additives.
As shown in Figure 17, the solubility of Brinzolamide increases with the increase in the concentration of HP in both the cases (with and without Timolol). The solubility of Brinzolamide in absence of Timolol with 0.5% (w/v) HP and 1% (w/v) Polysorbate 80 is about 1 1 mg/mL. The addition of PEG 8000 over PEG 400 seems to enhance the solubility of Brinzolamide. However, the solubility for control solution as well as all the formulations with additives containing 0.5% (w/v) Timolol was relatively lower. Thus, Timolol, which is relatively more soluble in water than Brinzolamide at pH 7, makes an impact on aqueous solubility of Brinzolamide by its presence in the topical formulation sample. These results are very similar to the results (EXPERIMENTAL EXAMPLE 1) regarding another carbonic anhydrase called Dorzolamide. The decrease in solubility by highly soluble ionic Timolol at pH 7 could be due to change in ionic strength of the solution by addition of Timolol or salting out effect. While the market AZARGA® product has Brinzolamide 10 mg/mL+Timolol 5 mg/mL ophthalmic suspension at pH 7.4, the enhancement of solubility at pH 7 by addition of HP or PEG will have useful contribution to efficacy enhancement of drug by increasing the dosage to greater than 1%.
The addition of Polysorbate 80 to HP increases the Brinzolamide solubility by preventing the precipitation. Polysorbate 80 may act as a surfactant thereby reducing the aggregation of Brinzolamide after phase separation in presence of HP. A combination of 0.5% (w/v) HP and 1% (w/v) Polysorbate could be very effective in the presence of 0.5% (w/v) Timolol formulation at pH 7.
The improvement in aqueous solubility of Brinzolamide in presence of Timolol was significant with the additions of HP or a combination of PEG and Polysorbate 80 at pH 7. The Polysorbate 80 helps in dispersing the Brinzolamide molecules and inhibits the precipitation in water in presence of PEG. A combination of HP and Polysorbate 80 could be good combination for enhancement of Brinzolamide solubility in presence of Timolol at pH 7. From the results, it can be concluded that HP and Polysorbate 80 significantly enhance the solubility of hydrophobic Brinzolamide in presence of Timolol at pH 7. Hydrophilic PEG also turned out to be a Brinzolamide solubility enhancer. Furthermore, a combination of low concentrations of Polysorbate 80 and PEG 8000 also proved to be a very useful additive for enhancement of solubility of hydrophobic Brinzolamide. Overall, a formulation at pH 7 with optimized concentration of HP and Polysorbate 80 could be very useful for increasing the ocular bioavailability.
Conclusion
The results clearly indicate the advantages of using HP and Polysorbate 80 as hydrophobic Brinzolamide solubility enhancing additives at pH values closer to physiological pH. Polysorbate 80 also proved to be an effective emulsifier suppressing the precipitation of poorly soluble Brinzolamide at pH 7 in presence of HP. Timolol may have an effect on the solubility of Brinzolamide by changing the ionic strength of the solution.
EXPERIMENTAL EXAMPLE 6
In vitro corneal permeation study of Dorzolamide and Timolol containing a HP with terminal hydroxyl groups.
In vitro experiments on corneal permeation of Dorzolamide and Timolol (active ingredients of COSOPT®) were carried out to investigate the effect of the addition of a hyperbranched polyester with hydroxyl functional groups in comparison to the original market topical formulation (only active ingredients).
A novel formulation containing the commercially available HP called Boltorn® H20. The generic definition of Boltorn® H20 is a HP with polyester core and 16 terminal hydroxyl functional groups. It enhances the solubility of non-ionic (lipophilic) Dorzolamide that is formulated at pH 7 or pH 7.4.
Figure imgf000039_0001
Generic structure of hyperbranched polyester with hydroxyl terminal groups.
The properties of HP used in this example are listed in Table 8. It has 16 primary hydroxyl groups per molecule. The solid content is 100% (w/v).
Figure imgf000039_0002
Table 8 : Properties of HP used in this example.
The in vitro transcorneal permeation of Dorzolamide and Timolol was determined from a novel formulation containing up to 2% (w/v) HP. The effect of the concentration of HP on the active ingredients was also determined. A standard solution containing COSOPT® active ingredients at pH 7.4 was used as a control sample. Materials and Methods
Formulation Preparation
The following three solutions in 0.1 % (w/v) phosphate buffer (Table 9) were formulated for examining the in vitro corneal permeation of Dorzolamide and Timolol, as well as for determining the corneal hydrolysis effect.
Figure imgf000040_0001
Table 9: Composition of Test Formulations.
First, the 10 mM phosphate buffer was added to the appropriately weighed mass of solid active ingredients and stirred thoroughly for 15 minutes. Secondly, the effective volume of 5% (w/v) HP suspension solution was added to Test Sample 2 and Test Sample 3 to make up the exact concentrations described in Table 9.
The three test solutions were then stirred for 10 minutes at room temperature (with heating up to 60 °C for 5 minutes). After stirring, the solution was sonicated for 5 minutes. Apart from the control solution (Control Sample # 1 ), the solutions with HP were white slurry suspensions before adjusting the pH. After allowing the complete dilution of all the active and non-active ingredients, the pH was adjusted to 7.4 by using 1 M NaOH or 1 M HC1, and additional buffer was added to make up the exact composition as in Table 8. With the adjustment of pH, suspension solutions were formed in all cases, which were equilibrated by stirring for an additional 15 hours or more at room temperature. The pH of all the sample solutions was measured again to confirm the final desired pH.
These suspension solutions were used directly as sample donor solutions for the cornea permeation study. In order to determine the solubility, the suspensions were filtered through 0.45 μηι syringe filters. The filtrates were analyzed for Dorzolamide and Timolol concentrations using UPLC, after diluting each sample with ultrapure water (dilution factor = 1000). The in vitro cornea permeation profile results were also compared to the data obtained at pH 5.65 for the control sample containing active ingredients from EXPERIMENTAL EXAMPLE 4.
Three male rabbits (New Zealand) weighing 2 to 3 kg. Immediately after sacrifice by an overdose of inhaler isoflurane, the eyes were enucleated, and the corneas were separated for use in the permeation experiments. The details of the experimental procedure are described in previous EXPERIMENTAL EXAMPLE 4.
The calculated parameters that were calculated are as described in EXPERIMENTAL EXAMPLE 4, with Ca [ng/mL] being the initial drug concentration of active pharmaceutical ingredient in donor solution (Table 10).
Results and Discussion
The initial concentrations of Dorzolamide and Timolol determined by UPLC are given in Table 10. The percentage corneal hydration calculations are given in Table 10.
Figure imgf000041_0001
Sample Final net wet weight Final net dry weight % (w/w) Corneal
(R) (B) hydration
Test 1 0.0104 0.0020 80.7
Test 1 0.0124 0.0022 82.2
Test 2 0.01 17 0.0025 78.6
Test 2 0.0126 0.0024 80.9
Test 3 0.0146 0.0029 80.1
Test 3 0.01 13 0.0026 76.9
Table 11: Percentage corneal hydration calculation.
The corneal hydration was measured based on the net wet weight and dry weight of the cornea. Typically, the % hydrations for a cornea in a normal mammal are in the range of 75- 80%. Overall, there was no significant change in the % hydrations for all the test samples, and they were within the desired range in all the cases. Thus, the HP did not have impact on corneal hydration.
Figures 18 and 19 reveal the corneal permeation profiles of Dorzolamide and Timolol, respectively. The control sample permeation profile at pH 5.65 from EXPERIMENTAL EXAMPLE 4 was also plotted along with the permeation profiles obtained for Test sample 1 , 2 and 3. The time dependent permeation of Dorzolamide and Timolol was carefully examined across the isolated rabbit cornea at 34 °C. The Dorzolamide cumulative total amount permeated through the cornea, and the total amount permeated after 2 hours was relatively higher for the test formulation containing 0.5% (w/v) HP (Test 2) and 2% (w/v) HP (Test 3) compared to the control sample with no additives. Furthermore, the increased concentration from 0.5% HP to 2% HP showed an increase in the corneal permeation of both active ingredients. In the formulation containing 2% (w/v) HP (Test 3), the corneal permeation of active ingredients is higher than the market product COSOPT® (only active ingredients in the formulation) at pH 5.65 (see Figure 19 and Figure 20). In addition, the formulation containing 2% (w/v) HP provided significant enhancement in corneal permeation after 2 hours with a higher permeation rate (change in the slope).
Overall, the addition of a HP with hydroxyl functional groups enhances the corneal permeation rate of Dorzolamide and Timolol significantly, with an increase in the concentration of HP. Thus, HP improved the corneal penetration of active ingredients, when compared to the market products known as COSOPT® or TRUSOPT® or AZOPT®, which are used for glaucoma treatment.
Figure 20 shows the percentage total permeation of Dorzolamide and Timolol after 2 hours. Clearly, the presence of HP increased the percentage of active ingredients (Dorzolamide and Timolol) permeated through the cornea. It should be noted that all test formulations had different initial concentrations in the case of Dorzolamide, and similar concentrations of Timolol (less than 10% change). Different initial solubility of Dorzolamide is mainly because of the increased solubility by HP. In Test 2 and Test 3 in comparison with Test 1 , the significance of using HP as an additive it is clear from Figure 20. The slopes from Figure 19 and 20 up to 2 hours were used in order to determine the corneal permeability, partition coefficient and diffusion coefficient.
Figure 21 shows the corneal permeability coefficients of Dorzolamide and Timolol. The permeability coefficient was inversely proportional to the initial concentration of the drug in the donor solution. In the case of both active ingredients, the permeability coefficients for Test 2 and Test 3 are higher, suggesting that dorozamide in the presence of HP has an enhanced corneal permeability rate compared to the control formulation (Test 1 ) containing no HP. Test 3 had a relatively higher corneal permeability than Test 2, thereby indicating the influence of increasing the concentration of HP. Overall, the data from Figure 21 clearly indicates that the permeability coefficients of Timolol and Dorzolamide were higher for formulation Tests 2 and 3 containing HP, in comparison to the Control Test 1 without HP at pH 7.4, and the COSOPT® control formulation at pH 5.65 (similar to COSOPT® active ingredient formulation).
The diffusion coefficient of Dorzolamide and Timolol, which is inversely proportional to the lag time, did not change significantly by the addition of HP (see Figure 22). Thus, HP does not have any impact on the corneal surface. If the diffusion coefficient would have increased or decreased significantly, it would indicate the change in corneal surface properties. Since the diffusion coefficient is an inherent property of the drug compound, it should not change with the addition of additives.
HP promotes the encapsulation of Timolol and Dorzolamide, and thus enhances the partitioning of Timolol and Dorzolamide into the corneal epithelium. This theory is also supported by the data suggested in Figure 23. The Timolol and Dorzolamide partition coefficient to the corneal surface for Tests 2 and 3 were higher than Test 1 , indicating the improvement in partitioning of Timolol and Dorzolamide into lipophilic corneal membrane in the presence of highly functional (hydroxyl group) HP. Thus, the improved permeation in the presence of HP is mainly because of improved partitioning to the epithelium. The permeation was further enhanced by increasing the concentration of HP in the formulation solution from 0.5 % to 2% (w/v). However, the partition coefficient and permeability coefficient did not change significantly by increasing the concentration of HP, since these parameters will not be a function of the concentration of the material.
The cumulative amount permeated of Dorzolamide and Timolol at pH 7.4 in the presence of HP additives, such as commercially available Boltorn® H20 with hydroxyl functional group, was relatively high, compared to the control formulation with no additives. The increase in concentration of such HP in the formulation enhanced the corneal permeation rate of Dorzolamide and Timolol significantly. The corneal permeability coefficients of Dorzolamide and Timolol were relatively higher in the presence of HP. The partitioning of active ingredients into the corneal epithelium increased in the presence of HP. Thus, an HP with hydroxyl functional groups could be very effective for increasing the ocular bioavailability of COSOPT® active ingredients.
EXPERIMENTAL EXAMPLE 7
The aqueous solubility of carbonic anhydrase inhibitors, such as Dorzolamide and Brinzolamide, in the presence of HP and Timolol at pH 7.4 in 10 mM phosphate buffer was studied. A HP called Boltorn® W3000 was used. The terminal functional groups of this HP are PEG (hydrophilic) and unsaturated long chain fatty acids. The model of the hyperbranched polyester used in this example is shown below.
Dendritic ba kbon
Figure imgf000045_0001
Hyperbranched polyester with amphiphilic terminal groups. The properties of HP used in this experiment are described in Table 12. The HP has 50 primary hydroxyl groups per molecule, and the solid content is 55% (w/w).
Figure imgf000046_0001
Table 12: Properties of HP used in this study.
Table 13 shows the different test samples formulations which were prepared in 10 mM phosphate buffer at pH 7.4.
Figure imgf000046_0002
Table 13: Different Test formulations prepared in phosphate buffer at pH7
The emulsion was prepared by slowing dispersing water to the weighed amount of waxed Boltorn® W3000 to make 5% (w/v) emulsion with continuous stirring and heating at 60-70 °C for at least 30 minutes, followed by continuous vigorous stirring for an additional 15 hours, to obtain a homogeneous emulsion mixture in a flask. 10 mM phosphate buffer was added to the appropriately weighed mass of solid active ingredients and stirred thoroughly for 15 minutes. Secondly, the effective volume of 5% (w/v) HP emulsion solution was diluted appropriately to make up the exact concentrations described in Table 13. The sample test emulsion solutions were then stirred for 10 minutes at room temperature (with heating up to 60 °C for 5 minutes). After stirring, the emulsion solution was sonicated for 5 minutes. After allowing the complete emulsion of all the active and non-active ingredients, the pH was adjusted to 7.4 by using 1 M NaOH, and additional buffer was added to make up the exact compositions in Table 13. With the adjustment of the pH, the emulsion solutions were further equilibrated by stirring for an additional 15 hours or more at room temperature. The pH of all the sample emulsion solutions was measured again to confirm the final desired pH of 7.4. The filtrates were analyzed for CAI concentration using UPLC with the same condition as EXPERIMENTAL EXAMPLE 1.
Results & Discussion
In this experiment, an amphiphilic self emulsifying HP was used as a solubility enhancer additive. Different concentrations of the HP were attempted at pH 7.4.
In Figure 24, the solubility of Brinzolamide and Dorzolamide is shown to increase with the increase in the concentration of HP. The solubility of Dorzolamide and Brinzolamide in the presence of 0.5% (w/v) Timolol with 5% (w/v) HP is about 2% (w/v) of CAI. The addition of HPMC to 2% (w/v) HP did not enhance the solubility. While the market AZARGA® suspension product has 1 % (w/v) Brinzolamide at pH 7.4, and COSOPT® has 2% (w/v) Dorzolamide at pH 5.65, the enhancement of solubility at pH 7.4 by the addition of HP will have a useful contribution to the efficacy enhancement of the drug by increasing the dosage to greater than 1 % (w/v). Therefore, it is important to develop a Brinzolamide or Dorzolamide with enhanced solubility close to pH 7.4 (pH of tear fluid is 7.4) in order to enhance ocular bioavailability and to decrease eye irritation appearance of CAIs.
EXPERIMENTAL EXAMPLE 8
In vitro corneal permeation study of Dorzolamide and Timolol containing HP with amphiphilic functional groups (Boltorn® W3000).
In vitro experiments on corneal permeation of Dorzolamide and Timolol (active ingredients of COSOPT®) were carried out to investigate the effect of the addition of a HP with amphiphilic functional groups in comparison to the original market topical formulation (only active ingredients).
A new topical formulation containing Boltorn® W3000 (hyperbranched polyester) with non-ionic PEG as hydrophilic functional groups and unsaturated fatty acid as hydrophobic functional groups (commercially available), thus making it amphiphilic. The solubility of Dorzolamide was increased from 4.3 to 15 mg/mL by adding 2% (w/v) of this HP at pH 7.41. In this experiment, the in vitro transcorneal permeation of Dorzolamide and Timolol was determined from a novel formulation containing up to 2% (w/v) HP that was comparable to COSOPT®. The effect of concentration of HP on the active ingredients was also determined. A standard solution containing COSOPT® active ingredients at pH 7.4 was used as a control sample.
Materials and Methods
1. Formulation Preparation The following three solutions in 0.1 % (w/v) phosphate buffer (Table 14) were formulated for examining the in vitro corneal permeation of Dorzolamide and Timolol, as well as determining the corneal hydrolysis effect.
Figure imgf000049_0001
Table 14: Composition of test formulations
10 mM phosphate buffer was added to the appropriately weighed mass of the solid active ingredients, and stirred thoroughly for 15 minutes. Secondly, the effective volume of 5% (w/v) HP suspension solution was added to Test 2 to make up the exact concentrations as in Table 14. The three test solutions were then stirred for 10 minutes at room temperature (with heating up to 60 °C for 5 minutes). After stirring, the solution was sonicated for 5 minutes. After allowing the complete dilution of all the active and non-active ingredients, the pH was adjusted to either 7.4 or 5.65 by using 1 M NaOH or 1 M HCl, and additional buffer was added to make up the exact compositions in the Table 15. With the adjustment of pH, the appearance was noted as per Table 14, and the formulations were further equilibrated by stirring for an additional 15 hours or more at room temperature. The pH of the all sample solutions was measured again to confirm the final desired pH. These formulations were used directly as sample donor solutions for the cornea permeation study. In order to determine the solubility, the suspension/emulsions were filtered through 0.45 μηι syringe filters. The filtrates were analyzed for Dorzolamide and Timolol concentration using UPLC after diluting each sample with ultrapure water (dilution factor = 1000).
2. In vitro rabbit corneal permeation experiment
The experimental procedure and analysis to be performed are described in detail in previous EXPERIMENTAL EXAMPLE 4. The parameters that were calculated are those described in EXPERIMENTAL EXAMPLE 4, where Cd [ng/mL] is the initial drug concentration of active pharmaceutical ingredient in donor solution (from Table 15).
Results and Discussion
The initial concentrations of Dorzolamide and Timolol determined by UPLC are given in Table 15. The percentage corneal hydration calculations are given in Table 16.
Figure imgf000050_0001
Table 15: Solubility of active pharmaceutical ingredient in test formulations.
Figure imgf000050_0002
Table 16: Percentage corneal hydration calculation. The corneal hydration was measured based on the net wet weight and dry weight of the cornea. Typically, the % (w/w) hydrations for a cornea in a normal mammal are in the range of 75-80%. Tests 1 and 3 are both above 80%. However, there is no difference in the calculated values of partition and permeability coefficient, suggesting that there could not be any corneal damage due to higher hydration %. Overall, there was no significant change in the % hydrations for all the test samples, which were within the desired range in all the cases. Thus, the HP did not appear to have an impact on corneal hydration.
Figures 25 and 26 reveal the corneal permeation profiles of Dorzolamide and Timolol, respectively. The time dependent permeation of Dorzolamide and Timolol was examined carefully across the isolated rabbit cornea at 34 °C. The Dorzolamide cumulative total amount permeated through the cornea, and the total amount permeated after 2 hours was relatively higher for the test formulation containing 2% (w/v) HP (Test 2) compared to the control sample with no additive at pH 7.4 (Test 1 ). The total permeation of Dorzolamide of Test 2 (novel formulation) was comparable to the Test 3 permeation profile for Dorzolamide. However, it should be noted that Test 1 could be more comfortable for the patient since it is prepared at pH 7.4, compared to the market product which is prepared at pH 5.65. The permeation could be further increased by increasing the concentration of the HP.
Furthermore, the Timolol permeation significantly increased in the presence of HP for Test 2 compared to Tests 1 and 3 having similar aqueous solubility, unlike Dorzolamide (see Figure 26). In the formulation containing 2% (w/v) HP (Test 2), the corneal permeation of Timolol is almost two times higher than the market product COSOPT® (only active ingredients in the formulation) at pH 5.65 (see Figure 27). This result clearly demonstrates the importance of using HP as a drug carrier for a topical formulation, for both Dorzolamide and Timolol. Overall, the addition of HP with amphiphilic functional group enhances the corneal permeation rate of Dorzolamide and Timolol significantly, with an increase in the concentration of HP. Thus, a dendritic polyester HP with amphiphilic functional groups improves the corneal penetration of active ingredients compared to the market products, known as COSOPT® or TRUSOPT® or AZOPT®, which are used for glaucoma treatment.
Figure 27 shows the percentage total permeation of Dorzolamide and Timolol after 3 hours. Clearly, the presence of HP increases the percentage of the active ingredients (Dorzolamide and Timolol) permeated through the cornea (see Test 2). Test 2, prepared at pH 7.4, had a Dorzolamide total % permeation which was slightly greater than Test 3, which is prepared at pH 5.65. It should be noted that all test formulations have different initial concentrations in case of Dorzolamide, and similar concentrations of Timolol. Different initial solubility of Dorzolamide is mainly because of the increased solubility by the HP. In Test 2, in comparison with Test 3 (pH 5.65) and Test 1 (pH 7.4), Figure 27 demonstrates the significance of using HP as an additive. The slopes from Figure 26 and 27 were used in order to determine the corneal permeability, partition coefficient and diffusion coefficient.
Figure 28 shows the corneal permeability coefficients of Dorzolamide and Timolol. The permeability coefficient is inversely proportional to the initial concentration of the drug in the donor solution. In the case of both active ingredients, the permeability coefficients for Test 2 are higher compared to the control samples at pH 7.4 and pH 5.65, thus suggesting that active pharmaceutical ingredient in presence of HP has enhanced corneal permeability rate compared to the control formulations (Tests 1 and 3) containing no HP. Test 3 had relatively higher corneal permeability than Test 2, thereby indicating the influence of pH. The active pharmaceutical ingredient at physiological pH is more conducive for permeation for similar solubilities. Overall, the data from Figure 28 clearly indicates that the permeability coefficients of Timolol and Dorzolamide were higher for the formulation of Test 2 containing HP, in comparison to Test 1 without HP at pH 7.4, and COSOPT® control formulation at pH 5.65 (similar to COSOPT® active ingredient formulation).
The diffusion coefficient of Dorzolamide and Timolol, which is inversely proportional to the lag time did not change significantly by the addition of HP (see Figure 29). Thus, HP does not have any impact on the corneal surface. If the diffusion coefficient would have increased or decreased significantly, it would indicate the change in corneal surface properties. Since the diffusion coefficient is the inherent property of drug compound, it should not change with the addition of additives.
The Timolol and Dorzolamide partition coefficients to the corneal surface for Test 2 were higher than Tests 1 and 3, thus indicating the improvement in partitioning of Timolol and Dorzolamide into lipophilic corneal membrane in the presence of a highly functional (amphiphilic) HP. Thus, the improved permeation in the presence of HP is mainly because of improved partitioning to the epithelium. The permeation can be further enhanced by increasing the concentration of HP in the formulation solution from 2% to 5% (w/v).
The cumulative amount permeated of Dorzolamide and Timolol at pH 7.4, in the presence of HP additives, such as commercially available Boltorn® W3000 with amphiphilic functional group (2% w/v), was almost 2 times higher compared to the control formulation at similar pH values, with no additives. The increase in concentration greater than 2% (w/v) of such HP in the formulation could further enhance the corneal permeation rate of Dorzolamide and Timolol significantly compared to the market product at pH 5.65. The novel topical formulation is prepared at pH 7.4, thus making it more conducive and comfortable for the patients. The partitioning of active ingredients into the corneal epithelium increased in presence of HP. Thus, HP with amphiphilic functional groups could be very effective for increasing the ocular bioavailability of COSOPT® active ingredients.
EXPERIMENTAL EXAMPLE 9
Solubility enhancement of carbonic anhydrase inhibitor (CAI) by Bis-MPA polyester hyperbranched polymer (BMPA-HP) or a combination of PEG and BMPA-HP.
The influence of functionalized hyperbranched polymers on the aqueous solubility of a CAI, such as Dorzolamide and Brinzolamide, in the presence of Timolol at pH 7.4 in 10 mM phosphate buffer was studied. The generic definition of BMPA-HP is a hyperbranched polymer with dimethylolpropionic acid (Bis-MPA) polyester core and terminal hydroxyl (OH) functional groups. The number of terminal hydroxyl functional groups depends on the generation of the hyperbranched polyester. The generation is defined by the number of branching layers or the extent of branching from the core to the terminal functional groups. For example, the 2nd generation BMPA hyperbranched polyester contains 16 hydroxyl groups while the 3rd generation contains 32 hydroxyl groups. The structure of BMPA-HP is shown below.
Figure imgf000055_0001
Hyperbranched bis-MPA polyester generation 3. (3rd BMPA-HP)
The properties of the polyester HPs of different generations used in this research study are listed in Table 17.
Figure imgf000055_0002
Table 17: Properties of HP used in this experiment
Materials and Methods
Table 18 shows the different test sample emulsions, except the control solution, to be prepared in 10 mM phosphate buffer at pH 7.4.
Figure imgf000056_0001
Figure imgf000056_0002
Table 18: Different test formulations prepared in phosphate buffer at pH 7.4
10 mM phosphate buffer was added to the appropriately weighed mass of solid active ingredients and stirred thoroughly for 15 minutes. Secondly, the effective volume of 5% (w/v) BMPA-HP solution was diluted appropriately to make up the exact concentrations described in Table 18. The sample test solutions were then stirred for 10 minutes at room temperature (with heating up to 60 °C for 5 minutes). After stirring, the solution was sonicated for 5 minutes. After allowing the complete suspension of all the active and non-active ingredients, the pH was adjusted to 7.4 using 1 M NaOH, and additional buffer was added to make up the exact compositions described in Table 1 8. With the adjustment of pH, suspension solutions were further equilibrated by stirring for an additional 15 hours or more at room temperature. The pH of the all sample solutions was measured again to confirm the final desired pH of 7.4. The filtrates were analyzed for CAI using UPLC with the same condition as EXPERIMENTAL EXAMPLE 1.
Results & Discussion
In this experiment, 2nd BMPA-HP or 3rd BMPA-HP were employed as solubility enhancer additives, and different concentrations of each were tested at pH 7.4. It is important to develop a lipophilic Brinzolamide or Dorzolamide drug with enhanced solubility close to pH 7.4 (pH of tear fluid is 7.4) in order to enhance ocular bioavailability and to decrease eye irritation appearance of CAIs. The solubility of Dorzolamide and Brinzolamide in the presence of 0.5% Timolol with 5% 3rd BMPA-HP is slightly about 1% (w/v) of CAI. With lower generation 2nd BMPA-HP, the solubility of CAI decreased by less than 10% in comparison to 3rd BMPA-HP for similar concentration of 2nd BMPA-HP used as an additive for all the samples.
When the combination of 2% (w/v) PEG 8000 and HP is used, the solubility of CAI increases dramatically (4 times more than the control). With the addition of 2% (w/v) PEG 8000 to 2% (w/v) BMPA-HP, the solubility of CAI almost doubled (see Figure 31).
While the market Azarga® suspension product has 1 % Brinzolamide at pH 7.4 and COSOPT® has 2% (w/v) Dorzolamide at pH 5.65, the enhancement of solubility at pH 7.4 by the addition of BMPA-HP will have useful contribution to efficacy enhancement of the drug, by increasing the dosage to greater than 1% (w/v).
The results clearly indicate the advantages of using BMPA-HP as a hydrophobic CAI solubility enhancer at pH values closer to physiological pH. The addition of PEG to the solution containing BMPA-HP further improved the solubility of CAI. EXPERIMENTAL EXAMPLE 10
Human Corneal Epithelium (HCE) tissue culture study of determining the eye irritancy of Bis-MPA hyperbranched polyester and the optimized sample application time for ophthalmic study based on the cytotoxicity of the cells.
Method and Materials
The samples were prepared in accordance with Table 19 below, in saline phosphate buffer (with the exception of AZOPT®) and sterilized using a 0.2 μπι sterile syringe filter. 0.02% BAK was used as a positive control. The reconstructed human corneal epithelium was purchased from Skin Ethics laboratory (France).
Figure imgf000058_0001
Table 19: Sample set.
The Cell Culture Method is described below:
Transfer epithelium from agarose to maintenance medium 6-well plate
1
Tissue conditioning: at least 2 hours at 37 °C, 5% C02) > 95% humidity
i
Transfer tissues to fresh maintenance medium in 24-well plates
1 3 tissues each with 30 / 30 mg test substances
1
Incubate at room temperature for 20 min or 40 min
i
Rinse with PBS
1
Transfer tissues to fresh maintenance medium
4
Incubate at 37 °C, 5% C02) > 95% humidity for 16 ± 1 hr
4
Transfer tissues into MTT solution in culture medium (MTT incubation)
4
Incubate tissues for 3 hours (37 °C, 5 % C02, > 95%)
4
Immerse the inserts in isopropanol (Formazan extraction)
4
Extract formazan minimum 2 hours (at room temperature)
4
Perforate the insert and homogenize
4
Read OD in a plate spectrophotometer at 570 nm
The percentage viability of each of the treated cultures was calculated from the percentage MTT conversion in the test chemical treated cultures relative to the corresponding negative controls (100% viable).
The following equation was used:
Percentage viability = [individual ODChemicai/mean ODnegatjve controi]xl 00.
HCE viability classification prediction model: NI (viability > 60%), I (viability < 60%), i.e., the product is classified as an irritant (according to in vivo classifications) if the percentage of viability compared to the negative control obtained for the test product is < 60%. Results and Discussion
As shown in Figure 32, the percentage viability of different samples (according to Table 19) was calculated using the equation for percentage viability described above, in the experimental section. Samples with viability of less than 60% were considered irritants. The standard deviation of the cell viability based on triplicates was less than 7% for all the samples. The results from the cytotoxicity study reveal that ophthalmic samples with up to 4% (w/v) of 3rd BMPA-HP will be a non-eye irritants, with greater than 60% cell viability. (See Figure 32.) The results from Figure 32 also reveal that AZOPT® could be cytotoxic against corneal epithelim cell with less than 50% cell viability for an application time of 1 hour. The sample containing 5% (w/v) Bis-MPA generation 2 also caused eye irritation with less than 60% cell viability.
Combining the results from previous studies, the cytotoxicity of Bis-MPA commercial hyperbranched polyester for different concentrations is revealed in Figure 33. It is evident from the Figure that the epithelial cell damage, and thus the eye irritation, caused by the 2nd BMPA- HP is less than the eye irritation caused by the 3rd BMPA-HP, for the same concentration in the ophthalmic solutions. It is known that the extent or length of branching and thus the molecular weight and number of terminal functional groups decrease with the decrease in the number of HP generations. The result from Figure 33 indicates that the decrease in cytotoxicity with the decrease in the number of generation could be mainly due to decrease in the prolonged interaction of the terminal functional groups with the epithelial cells.
Conclusions
The rate of epithelial cell death increased with the increase in the concentration dose and the generation (molar mass and extent of branching). In the case of the AZOPT® market product, it causes eye irritation with less than 50% cell viability, possibly due to 0.01% (w/v) of BAK with exposure time of one hour.
EXPERIMENTAL EXAMPLE 1 1
Solubility enhancement of CAI containing BMPA-HP or a combination of non-ionic surfactants and BMPA-HP.
The aqueous solubility and stability of Dorzolamide was studied in the presence of Timolol at pH 7.4 in 10 mM phosphate buffer.
Method and Materials
First, the 10 mM phosphate buffer was added to the appropriate weighed mass of solid active ingredients and stirred thoroughly for 15 minutes. After complete dissolution of active pharmaceutical ingredient, hyperbranched 2nd BMPA-HP was added to the solution. After HP was dissolved, PEG 8000 was added as per the formulation concentration needed. The sample test solutions were then stirred for 10 minutes at room temperature (with heating up to 60 °C for 5 minutes). After stirring, the solution was sonicated for 20 minutes. After allowing the complete dissolution of all the active and non active ingredients, the pH was adjusted to 7.4 by using 1 M NaOH and additional buffer was added to make up the exact compositions as per Tables 20 and 21. With the adjustment of pH, the formulations were further equilibrated by stirring for additional 15 hours or more at room temperature. The samples were filtered through 0.45 um syringe filter. Polysorbate 80 was added to the final formulation. In case of sample number 3, the formulation is equilibrated at 60 °C (24 hours) after pH adjustment, then Polysorbate 80 was added. The pH of all the sample solutions was measured again to confirm the final desired pH of 7.4. All samples were stored for 14 days at 25 and 60 °C, and the filtrates were analyzed for Dorzolamide and Timolol using UPLC after diluting each sample with ultrapure water (dilution factor = 1000).
Results & Discussion
Figure imgf000062_0001
Table 20: Contents of Dorzolamide and Timolol, Appearance and pH of Samples at room temperature.
Figure imgf000062_0002
Table 21 : Contents of Dorzolamide and Timolol, Appearance and pH of Samples at 60 °C. In this study, 2" BMPA-HP was studied as a solubility enhancer additive. Different combinations with non-ionic surfactants, such as PEG and Polysorbate 80, were attempted at pH 7.4. All the formulations were clear solutions at room temperature after sample preparation. In Figure 34, the solubility of Dorzolamide is shown to increase with the additions of 4% (w/v) HP and 2% (w/v) PEG. As shown in Figure 34, the concentration of Dorzolamide decreases steadily for the formulation containing 4% (w/v) HP and 2% (w/v) PEG from the 1st day up to 2 weeks. The formulation containing 4% (w/v) HP and 2% (w/v) PEG became a suspension after 2 weeks. The present inventors discovered that the rate of decrease of Dorzolamide concentration decreases with the addition of 1% (w/v) Polysorbate 80 (sample S#l ). The concentration of Dorzolamide decreased from 9.6 mg/mL to 8.4 mg/mL over a time period of two weeks.
Thus, higher concentration of Polysorbate 80 prevents the precipitation and helps stabilize the new formulation. Negligible change was observed in the pH of all the formulations over a period of 2 weeks (See Table 20 and Table 21). The change in Timolol concentration was insignificant over a period of two weeks. While the market AZARGA® suspension product has 1% (w/v) Brinzolamide at pH 7.4, and COSOPT® has 2% Dorzolamide at pH 5.65, the enhancement of solubility at pH 7.4 by addition of HP and non-ionic surfactants will have useful contribution to efficacy enhancement of drug by increasing the dosage to greater than equal to l % (w/v).
Conclusion
The results clearly demonstrate the advantages of using 2nd BMPA-HP in combination with PEG 8000 and Polysorbate 80 as CAI solubility enhancer at pH values closer to physiological pH.
EXPERIMENTAL EXAMPLE 12
A study to determine the topical formulation at pH 7.4, based on solubility and stability of carbonic anhydrase inhibitor (Dorzolamide and Brinzolamide) in the presence of Timolol in an aqueous solution containing different combinations of Hyperbranched bis-MPA polyester- 16- hydroxyl, generation 2 (2nd BMPA-HP), PEG 8000 and Polysorbate 80 in phosphate buffer was performed .
Methods and Materials
Table 22 shows all the different test samples to be prepared in 10 mM phosphate buffer at pH 7.4.
Figure imgf000064_0001
First, the 10 mM phosphate buffer was added to the appropriately weighed mass of solid active ingredients and stirred thoroughly until the active pharmaceutical agent was dissolved. Secondly, solid BMPA-HP powder was added to the sample formulations 1 , 2 and 3. After dissolution of the HP, the appearance was clear solution. The appropriate mass of non-ionic surfactants, such as PEG 8000, was added to the formulations to make up the exact concentrations as per the formulation content described in the above Table 22. All test solutions were then stirred for 10 minutes at room temperature (with heating up to 60 °C for 5 minutes). After stirring, the solution was sonicated for 5 minutes. After allowing the complete dissolution of all the active and non active ingredients, the pH was adjusted to 7.4 or 5.65 by using 1 M NaOH or 1 M HC1, and additional buffer was added to make up the exact compositions in accordance with the Table 22 sample compositions. With the adjustment of pH, test solutions were formed, which were equilibrated by stirring for an additional 24 hours or more at room temperature. For the samples that contain Polysorbate 80 and hyperbranched polyester (Table 2), Polysorbate 80 was only added after 24 hours of equilibration at 60 °C of the final formulation. The pH of the all the sample solutions was adjusted again to confirm the final desired pH.
The filtrates were analyzed for carbonic anhydrase inhibitors, Timolol and HP concentration using UPLC after diluting each sample with ultrapure water (dilution factor = 1000). The optimal conditions obtained from the EXPERIMENTAL EXAMPLE 1 for CAI and Timolol detection were used. The appearance and pH of each formulation is recorded over a period of 1 month at room temperature and 60 °C. Results and Discussion
This study used a HP with hydroxyl terminal groups, PEG, and Polysorbate 80 as solubility enhancer additives. Different combinations were attempted at pH 7.4 in order to determine the best formulation based on the previous results. Figure 35 demonstrates that the solubility of Dorzolamide increased significantly in the presence of 4% (w/v) HP and 2% (w/y) PEG or 4% (w/v) Polysorbate 80 (Sample 1 , 2 and 3). However, the Dorzolamide solubility did not increase significantly in the presence of PEG 8000 (sample 5) or Polysorbate 80 (sample 6) exclusively, or their combination (sample 4). Thus, hyperbranched polyester addition to the formulation clearly indicates its advantage as a solubility enhancer. However, the formulation containing HP with hydroxyj group in combination with Polysorbate 80 (sample 2) has similar solubility in comparison to the formulation containing HP, Polysorbate 80 and PEG 8000 (sample 1 ). Thus, the addition of PEG 8000 could be avoided. Overall, it was discovered that sample 2 is the best formulation, based on the Dorzolamide and Timolol solubility data. The addition of surfactants such as Polysorbate 80 to HP also increases the Dorzolamide solubility by preventing the precipitation of Dorzolamide encapsulated within HP.
Control S#l S #2 ■ S#3 S#4 S#5 S#6
Dorzolamide Initial 4.6 10.4 10.1 9.1 5.4 5.2 5.0
1 W 4.6 10.1 10.0 8.2 5.2 4.9 4.9 (mg/mL) 2 W 4.6 10.1 10.1 6.2 5.1 4.8 4.8
4W 4.5 10.1 10.1 5.9 5.0 4.8 4.6
Initial 5.2 5.1 5.1 4.9 5.1 5.2 5.0
Timolol (mg/mL) 1 W 5.1 5.0 5.1 4.9 5.1 5.1 5.0
2 W 5.0 4.9 5.1 4.9 5.1 5.1 5.0
4 W 5 4.9 5.1 4.8 5.1 5.0 4.9
Initial suspension clear clear clear suspension suspension suspension
Appearance 1 W suspension clear clear suspension suspension suspension suspension
2 W suspension clear clear suspension suspension suspension suspension
4 W suspension clear clear suspension suspension suspension suspension
Initial 7.40 7.40 7.40 7.39 7.40 7.40 7.39
PH 1 W 7.40 7.40 7.40 7.39 7.40 7.80 7.39
2 W 7.37 7.38 7.38 7.37 7.38 7.37 7.39
4 W 7.35 7.36 7.37 7.37 7.37 7.36 7.38
Table 23: Contents of Dorzolamide and Timolol, appearance and pH of samples at room temperature.
Figure imgf000067_0001
Table 24: Contents of Dorzolamide and Timolol, appearance and pH of samples at 60 °C. Tables 23 and 24 demonstrate the stability test results of Dorzolamide and Timolol over a period of 4 weeks for all the formulation samples. It is evident from the Table that sample # 1 and sample #2 are relatively stable and clear solutions after 1 month. The presence of PEG in sample # 1 could be avoided since sample #2 without PEG gives similar results.
Conclusion
The results clearly indicate the advantages of using HP with hydroxyl terminal functional groups in combination with surfactants such as Polysorbate 80 and PEG 8000. The surfactant behavior of Polysorbate 80 is very helpful for increasing the solubility of CAI by preventing the precipitation. The good formulation based on the solubility and 1 month stability results is a formulation containing active ingredients with a combination of 4% (w/v) 2nd BMPA-HP and 4% Polysorbate 80 only in phosphate buffer at pH 7.4.
EXPERIMENTAL EXAMPLE 13
In vitro corneal permeation study of Dorzolamide and Timolol for novel topical formulation containing Bis MPA hyperbranched polyester and Polysorbate 80.
Methods and Materials
The following three solutions in 0.1% (w/v) phosphate buffer (Table 27) were formulated for examining the in vitro corneal permeation of Dorzolamide and Timolol, as well as for determining the corneal hydrolysis effect.
Figure imgf000069_0001
Table 25: Composition of test formulations.
First, the 10 mM phosphate buffer was added to the appropriately weighed mass of solid active ingredients and stirred thoroughly for 15 minutes. In case of sample numbers 2 and 3, 2nd BMPA-HP powder was added to the solution as per the composition in Table 25. The three test solutions were then stirred for 10 min at room temperature (with heating up to 60 °C for 5 minutes). After stirring, the solution was sonicated for 5 minutes. After allowing the complete dissolution of all the active and non active ingredients, the pH was adjusted to 7.4 or 5.65 by using 1 M NaOH or 1 M HC1 and additional buffer was added to make up the exact composition as per the Table sample compositions. With the adjustment of pH, test solutions were formed which were equilibrated by stirring for additional 24 hours or more at room temperature for samples 1 and 2. In sample numbers 2 and 3, the equilibration was conducted for 24 hours at 60 °C. Polysorbate 80 (4% (w/v)) was then added followed by another pH adjustment. The pH of the all the sample solutions was measured again to confirm the final desired pH.
These clear solutions were used directly as sample donor solutions for the cornea permeation study. In order to determine the solubility, the test solutions were filtered through 0.45 μηι syringe filters. The filtrates were then analyzed for Dorzolamide and Timolol concentration using UPLC after diluting each sample with ultrapure water (dilution factor = 1000). The details of the materials and equipment used, as well as the rabbit cornea study procedure are given in EXPERIMENTAL EXAMPLE 4.
Results and Discussion
Figure imgf000070_0001
Table 26: Initial concentration of active ingredients in test samples.
The initial concentrations of Dorzolamide and Timolol determined by UPLC are given in Table 26.
Figure imgf000070_0002
Table 27: Percentage corneal hydration calculation.
The corneal hydration was measured based on the net wet weight and dry weight of the cornea. Typically, the % (w/w) hydrations for cornea in normal mammalian are in the range of 75-85%. Overall, there was no significant change in the % hydrations for all the test samples, and all were within the desired range, as shown in Table 27. Thus, the HP and Polysorbate 80 did not have impact on corneal hydration.
Figure 36 and Figure 37 reveal the corneal permeation profiles of Dorzolamide and Timolol, respectively. The time dependent permeation of Dorzolamide and Timolol was examined carefully across the isolated rabbit cornea at 34 °C. From Figure 36, the Dorzolamide cumulative total amount permeated through the cornea and the total amount permeated after 3 hours was relatively higher for the test formulation containing 4% (w/v) HP and Polysorbate 80 at pH 7.4 (Test 3) compared to the same formulation at pH 5.65 (Test 2). Clearly, Dorzolamide penetration is enhanced at pH 7.4 because of its non-ionic behavior which is very conducive for cornea epithelial membrane that is lipophilic. Dorzolamide cornea permeation for Test 3 is comparable to the control solution with no additives at pH 5.65 (Test 1). Notice that Test 3 contains 1 % (w/v) Dorzolamide while Test 1 contains 2% (w/v) Dorzolamide. While Test 3 contains half the Dorzolamide concentration of Test 1 , the cornea permeation profiles are similar. Test 3 could be more comfortable for the patient since it is prepared at pH 7.4 compared to the market product at pH 5.65 that can cause eye irritation. Timolol permeation profiles from Figure 37 suggest that Test 3 has significantly higher cornea permeation compared to Test 1 (control solution). Clearly, Timolol permeation is enhanced by the presence of hyperbranched polyester and Polysorbate 80 in Test 3 at pH 7.4 compared to Test 1 having similar aqueous solubility. Overall, enhanced Timolol permeation and comparable Dorzolamide permeation to the market product are key advantages of new formulation containing HP and Polysorbate 80. From Figure 38, the total percentage permeation of Dorzolamide and Timolol after 3 hours in case of Test 3 (novel formulation) was at least 2 times higher than Test 1 (market product active ingredients). Clearly, the presence of HP and Polysorbate 80 increase the percentage of active ingredients (Dorzolamide and Timolol) permeated through the cornea.
The slopes from Figure 36 and 37 were used in order to determine the corneal permeability coefficient and partition coefficient. The permeability coefficient is inversely proportional to the initial concentration of the drug in the donor solution. The permeability coefficients (see Figure 39) and partition coefficients (see Figure 40) of Test 2 are relatively higher than Test 1. Notice that both Test 1 and Test 2 solutions are at pH 5.65. The result suggests the influence of HP and Polysorbate 80 to enhance the partitioning and permeations of active ingredients. The permeability coefficient and partition coefficient of Test 3 is higher than Test 2 due to the pH effect. Test 3 formulation is prepared at pH 7.4 which is more conducive for permeation of non-ionic Dorzolamide and Timolol. Overall, the results clearly demonstrate the importance of using HP and Polysorbate 80 as drug carrier for a topical formulation for both Dorzolamide and Timolol.
Overall, the data from Figure 39 clearly indicates that the permeability coefficients of Timolol and Dorzolamide were higher for formulation Test 2 containing HP and Polysorbate 80, in comparison to the Test 1 without HP at pH 7.4 and COSOPT® control formulation at pH 5.65 (similar to COSOPT® active ingredient formulation).
HP and Polysorbate 80 promote encapsulation of Timolol and Dorzolamide, and thus enhance the partitioning of Timolol into corneal epithelium. This theory is also supported by the data in Figure 40. The Timolol and Dorzolamide partition coefficient to the corneal surface for Test 3 at pH 7:4 was the highest than Test 1 and Test 2 indicating the improvement in partitioning of Timolol and Dorzolamide into lipophilic corneal membrane in presence of highly functional HP at pH 7.4 rather than pH 5.65. Thus, the improved permeation in presence of HP is mainly because of improved partitioning to the epithelium.
Conclusion
The cumulative amount permeated of active pharmaceutical agent at pH 7.4 in the presence of HP additives such as commercially available dendritic Bis-MPA HP and Polysorbate 80 was almost comparable to the market product in case of Dorzolamide and more than 2 times higher for Timolol permeation. This novel topical formulation is prepared at pH 7.4, thus making it more conducive for lipophilic epithelial cornea penetration and comfortable for the patients. Thus, HP with hydroxyl terminal groups and Polysorbate 80 could be very effective for increasing the ocular bioavailability of COSOPT® active ingredients.
INDUSTRIAL APPLICABILITY
According to the present invention, an ophthalmic composition comprising a HP, which shows increased aqueous solubility of carbonic anhydrase inhibitors, such as Dorzolamide or Brinzolamide, can be provided. The ophthalmic composition may also comprise a non-ionic surfactant and/or a beta-blocker. The ophthalmic compositions of the present invention result in increased permeation of the active agent into the cornea. Therefore, the overall ocular bioavailability and hence the therapeutic activity of the topical ophthalmic solution containing a carbonic anhydrase inhibitor and beta blocker (active ingredients) can be increased compared to current relevant ophthalmic market products available. The topical ophthalmic compositions presented in this invention provide more potent anti-glaucoma compositions that may increase patient compliance by increasing ocular bioavailability.
While some of the embodiments of the present invention have been described in detail in the above, those of ordinary skill in the art can enter various modifications and changes to the particular embodiments shown without substantially departing from the novel teaching and advantages of the present invention. Such modifications and changes are encompassed in the spirit and scope of the present invention as set forth in the appended claims.

Claims

The invention claimed is:
(1) An ophthalmic composition comprising a hyperbranched polymer, wherein the hyperbranched polymer comprises a terminal functional group selected from the group consisting of an amine group, a hydroxyl group, a fatty acid group, and PEG.
(2) The ophthalmic composition according to claim 1 , further comprising a carbonic
anhydrase inhibitor.
(3) The ophthalmic composition according to claim 1, further comprising a non-ionic surfactant.
(4) The ophthalmic composition according to claim 2, further comprising a non-ionic surfactant.
(5) The ophthalmic composition according to claim 1, wherein the average molecular weight of the hyperbranched polymer is in the range from 1,000 to 750,000 Daltons (Mw).
(6) The ophthalmic composition according to claim 1 or 2, wherein the hyperbranched polymer comprises a core selected from the group consisting of Polyethylenimine, Polypropylenimine, and polyester.
(7) The ophthalmic composition according to claim 1, wherein the pH is in the range from
3.0 to 8.0.
(8) The ophthalmic composition according to claim 1, wherein the concentration of the hyperbranched polymer is in the range from 0.01% to 5% (w/v).
(9) The ophthalmic composition according to claim 2, further comprising a beta-blocker.
(10) The ophthalmic composition according to claim 2, wherein the carbonic anhydrase inhibitor is selected from the group consisting of Dorzolamide, Brinzolamide and Acetazolamide.
The ophthalmic composition according to claim 3, wherein the non-ionic surfactant is selected from the group consisting of PEG, polysorbate, Hydroxyl Propyl Methyl Cellulose, and Hydroxy Ethyl Cellulose.
The ophthalmic composition according to claim 4, wherein the non-ionic surfactant is selected from the group consisting of PEG, Polysorbate, Hydroxyl Propyl Methyl Cellulose, and Hydroxy Ethyl Cellulose.
The ophthalmic composition according to claim 9, wherein the beta-blocker is selected from the group consisting of Carteolol, Levobunolol, Betaxolol, Metipranolol, Timolol and Propranolol.
The ophthalmic composition according to claim 6, wherein the hyperbranched polymer core is polyester, and wherein the hyperbranched polymer comprises a hydroxyl group, a fatty acid group, and PEG as terminal functional groups.
The ophthalmic composition according to the claim 14, wherein the average molecular weight of the hyperbranched polymer is in the range from 1,000 to 12,000 Daltons (Mw).
The ophthalmic composition according to claim 14, wherein the concentration of the hyperbranched polymer is in the range from 0.001 to 4% (w/v).
An ophthalmic composition comprising a hyperbranched polyester, Timolol, Dorzolamide, and Polysorbate 80, wherein the hyperbranched polyester comprises a terminal functional group selected from the group consisting of a polyester hydroxyl group, a fatty acid group, and PEG. An ophthalmic composition comprising a hyperbranched polyester, Timolol, Brinzolamide, and Polysorbate 80, wherein the hyperbranched polyester comprises a terminal functional group selected from the group consisting of a polyester hydroxyl group, a fatty acid group, and PEG.
PCT/US2011/035147 2010-05-05 2011-05-04 Ophthalmic composition WO2011140194A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US13/695,930 US20130053374A1 (en) 2010-05-05 2011-05-04 Ophthalmic composition
MX2012012846A MX2012012846A (en) 2010-05-05 2011-05-04 Ophthalmic composition.
EP20110778244 EP2566487A4 (en) 2010-05-05 2011-05-04 Ophthalmic composition
CA2797123A CA2797123A1 (en) 2010-05-05 2011-05-04 Ophthalmic composition
CN2011800332340A CN103096901A (en) 2010-05-05 2011-05-04 Ophthalmic composition
JP2013509213A JP2013528589A (en) 2010-05-05 2011-05-04 Ophthalmic composition
KR1020127031915A KR20130121685A (en) 2010-05-05 2011-05-04 Ophthalmic composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/774,419 US8211450B2 (en) 2010-05-05 2010-05-05 Ophthalmic composition
US12/774,419 2010-05-05

Publications (1)

Publication Number Publication Date
WO2011140194A1 true WO2011140194A1 (en) 2011-11-10

Family

ID=44902332

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/035147 WO2011140194A1 (en) 2010-05-05 2011-05-04 Ophthalmic composition

Country Status (8)

Country Link
US (2) US8211450B2 (en)
EP (1) EP2566487A4 (en)
JP (1) JP2013528589A (en)
KR (1) KR20130121685A (en)
CN (1) CN103096901A (en)
CA (1) CA2797123A1 (en)
MX (1) MX2012012846A (en)
WO (1) WO2011140194A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013114397A2 (en) * 2012-01-16 2013-08-08 Biocon Limited Pharmaceutically acceptable salt of brinzolamide and composition thereof
WO2021018750A1 (en) 2019-07-26 2021-02-04 Proqr Therapeutics Ii B.V. Ophthalmic compositions comprising viscosifying polymers and nucleic acids

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130046437A (en) * 2010-07-29 2013-05-07 쓰키오카 필름 세이야쿠 가부시키가이샤 Drug support body, and method for producing same
US9820991B2 (en) * 2013-11-08 2017-11-21 Sentiss Pharma Private Limited Pharmaceutical composition comprising brinzolamide
CN103740831B (en) * 2014-01-13 2015-01-28 宁波海尔施基因科技有限公司 Primer combination for guiding application of beta-receptor blocker, multi-gene detection kit and using method thereof
UA118576C2 (en) * 2014-01-24 2019-02-11 Сентис Фарма Прайвет Лімітед Pharmaceutical composition comprising brinzolamide
MX2020008507A (en) 2014-05-16 2022-05-13 Occidental Chem Co Method for making 1,1,3,3-tetrachloropropene.
NZ728131A (en) * 2014-07-11 2017-09-29 Fujifilm Corp Aqueous ophthalmic composition
KR101773669B1 (en) 2015-07-30 2017-08-31 포항공과대학교 산학협력단 Biocompatibility keratocyte progenitor cell differentiation method and biocompatibility keratocyte progenitor cell composition
JP6050454B1 (en) * 2015-09-28 2016-12-21 参天製薬株式会社 Aqueous pharmaceutical composition
JP6178028B1 (en) * 2016-03-14 2017-08-09 参天製薬株式会社 Pharmaceutical composition containing dorzolamide, timolol and surfactant
PL3723739T3 (en) 2017-12-15 2024-09-16 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and their use for treating blepharitis
CN118613267A (en) * 2022-01-21 2024-09-06 千寿美国有限公司 Aqueous liquid preparation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060204472A1 (en) * 2003-02-13 2006-09-14 Constantinos Paleos Multifunctional dendrimers and hyperbranched polymers as drug and gene delivery systems
US20070048337A1 (en) * 2005-08-24 2007-03-01 Arthur Samuel D Aldol-crosslinked polymeric hydrogel adhesives
US20080180803A1 (en) * 2007-01-26 2008-07-31 Seybert Kevin W Optical elements comprising compatiblizing coatings and methods of making the same
US20100008993A1 (en) * 2008-07-14 2010-01-14 Proksch Joel W Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136014A (en) * 1990-06-22 1992-08-04 E. I. Du Pont De Nemours And Company Hyperbranched polyesters
RO113612B1 (en) * 1991-04-17 1998-09-30 Merck & Co Inc Ophtalmic composition
US6316443B1 (en) * 1994-08-04 2001-11-13 Merck & Co., Inc. Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
DE19726186A1 (en) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Complexes for the transport of nucleic acid into higher eukaryotic cells
FR2772771B1 (en) * 1997-12-19 2000-01-28 Oreal USE OF HYPERBRANCHED POLYMERS AND DENDRIMERS HAVING A PARTICULAR GROUPING, AS A FILM-FORMING AGENT, FILM-FORMING COMPOSITIONS COMPRISING THEM AND THEIR USE IN PARTICULAR IN COSMETICS OR PHARMACY
WO2000063409A1 (en) 1999-04-21 2000-10-26 Massachusetts Institute Of Technology Endosomolytic agents and cell delivery systems
US7030097B1 (en) 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
SK282717B6 (en) 2000-03-10 2002-11-06 �Stav Experiment�Lnej Farmakol�Gie Sav Preparation method of ultrahigh molecular hyaluronans
US7097856B2 (en) 2000-09-29 2006-08-29 The Regents Of The University Of California Dendrimeric support or carrier macromolecule
JP2004523624A (en) 2001-02-26 2004-08-05 デューク ユニバーシティ Novel dendritic polymer and its biomedical use
WO2002074323A2 (en) 2001-03-08 2002-09-26 Nymox Pharmaceutical Corporation Using neural thread proteins to treat tumors and other hyperproliferative disorders
FR2830450B1 (en) 2001-10-09 2004-02-06 Univ Pasteur USE OF DENDRIMERS IN AN OPHTHALMIC COMPOSITION
AR038269A1 (en) 2002-01-09 2005-01-12 Novartis Ag POLYMERIC ITEMS THAT HAVE A LUBRIC COATING, AND METHOD FOR MANUFACTURING THEM
GB0209022D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
WO2004060283A2 (en) 2002-12-16 2004-07-22 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
JP2005008614A (en) 2003-03-28 2005-01-13 Nano Career Kk Drug delivery system for ophthalmology by using macromolecular micelle
US7109247B2 (en) 2003-05-30 2006-09-19 3M Innovative Properties Company Stabilized particle dispersions containing nanoparticles
US7189456B2 (en) 2004-03-04 2007-03-13 Transitions Optical, Inc. Photochromic optical article
WO2006031358A2 (en) 2004-08-13 2006-03-23 Hyperbranch Medical Technology, Inc. Dendritic polymers, crosslinked gels, and their uses as ophthalmic sealants and lenses
US20060057215A1 (en) * 2004-09-15 2006-03-16 Raiche Adrian T Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
US7837986B2 (en) 2004-12-01 2010-11-23 E. I. Du Pont De Nemours And Company Protein-based polymer tissue adhesives for medical use
AR054227A1 (en) * 2005-02-21 2007-06-13 Basf Ag COMPOSITION OF ACTIVE PRINCIPLES
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US7666331B2 (en) 2005-08-31 2010-02-23 Transitions Optical, Inc. Photochromic article
JP5989294B2 (en) 2006-01-20 2016-09-07 スターファーマ・プロプライエタリー・リミテッドＳｔａｒｐｈａｒｍａ Ｐｔｙ Ｌｔｄ Modified polymer
US20090012033A1 (en) 2006-03-03 2009-01-08 Demattei Cordell R Delivery of Biologically Active Materials Using Core-Shell Tecto(Dendritic Polymers)
US20080031916A1 (en) * 2006-04-24 2008-02-07 Heather Sheardown Dendrimer cross-linked collagen
WO2008027340A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
US20090324742A1 (en) 2006-09-08 2009-12-31 Sonke Svenson Peham dendrimers as excipients
EP2409687B1 (en) * 2006-11-09 2014-06-11 Alcon Research, Ltd. Water insoluble polymer matrix for drug delivery
DK2214646T3 (en) * 2007-10-05 2021-10-04 Univ Wayne State DENDRIMERS FOR SUSTAINED RELEASE OF COMPOUNDS
US8426492B2 (en) 2007-11-14 2013-04-23 Actamax Surgical Materials, Llc Oxidized cationic polysaccharide-based polymer tissue adhesive for medical use
WO2010017184A2 (en) * 2008-08-08 2010-02-11 Virginia Commonwealth University Dendrimer hydrogels

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060204472A1 (en) * 2003-02-13 2006-09-14 Constantinos Paleos Multifunctional dendrimers and hyperbranched polymers as drug and gene delivery systems
US20070048337A1 (en) * 2005-08-24 2007-03-01 Arthur Samuel D Aldol-crosslinked polymeric hydrogel adhesives
US20080180803A1 (en) * 2007-01-26 2008-07-31 Seybert Kevin W Optical elements comprising compatiblizing coatings and methods of making the same
US20100008993A1 (en) * 2008-07-14 2010-01-14 Proksch Joel W Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HASSAN, E. ET AL., PHARM RES., vol. 5, 1990, pages 491
See also references of EP2566487A4

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013114397A2 (en) * 2012-01-16 2013-08-08 Biocon Limited Pharmaceutically acceptable salt of brinzolamide and composition thereof
WO2013114397A3 (en) * 2012-01-16 2013-10-17 Biocon Limited Pharmaceutically acceptable salt of brinzolamide and composition thereof
WO2021018750A1 (en) 2019-07-26 2021-02-04 Proqr Therapeutics Ii B.V. Ophthalmic compositions comprising viscosifying polymers and nucleic acids

Also Published As

Publication number Publication date
CN103096901A (en) 2013-05-08
CA2797123A1 (en) 2011-11-10
US8211450B2 (en) 2012-07-03
JP2013528589A (en) 2013-07-11
EP2566487A4 (en) 2014-06-18
US20110275617A1 (en) 2011-11-10
KR20130121685A (en) 2013-11-06
MX2012012846A (en) 2013-05-22
EP2566487A1 (en) 2013-03-13
US20130053374A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
EP2566487A1 (en) Ophthalmic composition
JP7368661B2 (en) pharmaceutical composition
JP2020015758A (en) Pharmaceutical nanoparticles showing improved mucosal membrane transport
JP5745666B2 (en) Ophthalmic and otic compositions of planar amphiphilic polymers and oligomers and uses thereof
KR102525438B1 (en) Preparation of Solid Cyclodextrin Complex for Ophthalmic Active Pharmaceutical Ingredient Delivery
JP6946001B2 (en) Pharmaceutical composition and salt of 1,2,4-oxadiazole benzoic acid
JP2004528267A (en) Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug
EA015336B1 (en) Nanoparticulate acetaminophen stable formulation
WO2010059894A1 (en) Ocular formulations of norketotifen
TW200942271A (en) Liposome for reaching posterior segment of eyeball and pharmaceutical composition for disease of posterior segment of eyeball
US9889088B2 (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
Ahmed et al. In situ gelling systems for ocular drug delivery
EP2827838B1 (en) Ophthalmic pharmaceutical composition containing a carbonic anhydrase inhibitor and method for the preparation thereof
Lu Recent advances in developing ophthalmic formulations: a patent review
Tripathi et al. Development of brimonidine niosomes laden contact lenses for extended release and promising delivery system in glaucoma treatment
US20240091179A1 (en) Ophthalmic pharmaceutical compositions and uses thereof
US20230218611A1 (en) Ophthalmic compositions comprising a combination of brinzolamide and brimonidine
US20130210876A1 (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180033234.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11778244

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2797123

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013509213

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13695930

Country of ref document: US

Ref document number: MX/A/2012/012846

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20127031915

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011778244

Country of ref document: EP